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RIASSUNTO 
 
Introduzione 
Gli antibiotici sono farmaci di grandissimo rilievo che hanno migliorato 
sostanzialmente la vita di milioni di persone. Tuttavia, il loro uso eccessivo ed 
inappropriato ha provocato lo sviluppo di ceppi batterici antibiotico-resistenti, 
rendendo inefficienti i trattamenti terapeutici attualmente in uso (Livermore D.M. 
2004). Secondo il rapporto dell’Ecdc (European Centre for Disease Prevention and 
Control), la resistenza agli antibiotici sia da parte dei batteri Gram-positivi che Gram-
negativi è in rapida ascesa. Inoltre è stata riscontrata una notevole disparità tra 
l’aumento della frequenza di ceppi resistenti e la produzione di nuovi farmaci. Per far 
fronte a questa emergenza, è sempre più urgente sviluppare nuovi agenti terapeutici  
che abbiano  una maggiore selettività ed  un meccanismo d'azione diverso da quelli 
degli antibiotici attuali.  
I peptidi antimicrobici e i batteriofagi potrebbero essere dei candidati ideali per la 
risoluzione del problema dell’antibiotico resistenza.  
I peptidi antimicrobici (CAMPs) sono ampiamente distribuiti in natura, essi sono 
diversi in termini di lunghezza, di struttura primaria e secondaria, ma possiedono  
due caratteristiche comuni: a pH fisiologico sono cationici e anfipatici. La carica 
positiva rende i peptidi antimicrobici selettivi per la membrana batterica ricca di 
fosfolipidi carichi negativamente (fosfatidilserina, fosfatidilglicerolo e 
bisfosfatidilglicerolo) (Zasloff M.  2002). Inoltre, i peptidi antimicrobici, avendo una 
sequenza segnale simile a quella presente nelle proteine cellulari, non vengono 
degradate facilmente dalle proteasi (Boman HG. 2003). La membrana delle cellule 
eucariotiche a differenza della membrana batterica è ricca di fosfolipidi switterionici 
(fosfatidilcolina, sfingomielina), quindi l`interazione elettrostatica con i peptidi non può 
avvenire (Chia CS. et al., 2011). I CAMPs hanno un’azione antimicrobica ad ampio 
spettro: risultano attivi contro batteri Gram-positivi e Gram-negativi, virus e funghi 
(Lai Y. et al., 2009), costituiscono la prima linea di difesa (Boman H.G. 2000), 
mettono in relazione l'immunità innata con quella acquisita (Vizioli J. et al., 2002) ed 
inoltre possono agire sia come molecole antimicrobiche nei confronti dei patogeni, 
che come agenti immunomodulatori della risposta immunitaria (Scott MG. et al., 
2007). Quest’ultima attività viene esplicata mediante: attivazione della chemiotassi, 
regolazione della produzione di citochine e stimolazione delle cellule del sistema 
immunitario, quali monociti e Antigen-Presenting Cells (APC). In aggiunta sono in 
grado di modulare il rilascio di istamina e migliorare l'angiogenesi, andando ad 
accelerare i meccanismi di cicatrizzazione delle ferite (Salzet M. et al.,  2002; Chen 
Q. et al., 2004). 
I batteriofagi o fagi sono parassiti intracellulari obbligati, in grado di moltiplicarsi solo 
all'interno della cellula batterica ospite. I batteriofagi furono scoperti da Hankins nel 
1896, il quale in modo del tutto fortuito notò l'esistenza di questi "agenti antibatterici" 
nei fiumi Gange (Sulakvelidze A. et al., 2001) e Jumna. Nel 1917, Felix d'Herelle 
(ricercatore presso l'Istituto Pasteur di Parigi) dimostrò l'attività antibatterica dei 
batteriofagi sulla Shigella dysenteriae nei conigli e chiamò questi agenti antimicrobici 
batteriofagi ("mangiatori" di batteri). Nel 1930, d`Herelle fondò in Georgia un istituto 
per lo studio dei batteriofagi, dove ancora oggi, i fagi sono regolarmente utilizzati per 
controllare le infezioni batteriche nell'uomo (Clokie M. et al., 2011). Questi procarioti 
sono la forma di vita più abbondante nella biosfera (Brüssow H. et al., 2005), ogni 
centimetro cubo di acqua contiene da 10 a 100 milioni di fagi (Sulakvelidze A. et al., 
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2001). Questi ultimi sono molto diversificati e questa diversità è determinata dalla 
loro capacità di adattamento dinamico per superare la pressione selettiva. Infatti, 
quando i fagi infettano le cellule batteriche, si trovano ad affrontare i meccanismi di 
difesa antivirali, per questo hanno sviluppato varie strategie per evitare, eludere o 
sovvertire questi meccanismi. I fagi possono essere classificati in base alla 
morfologia, al genoma, ed alla gamma degli ospiti. Il materiale genetico può essere 
dsDNA, ssDNA o RNA. La maggior parte dei fagi hanno un capside icosaedrico 
(contenente DNA) legato attraverso il collare ad una coda che può avere le spine e/o 
fibre; avendo un meccanismo di azione più specifico rispetto agli antibiotici, i fagi non 
comportano danni per l’organismo umano e per i batteri benefici, come quelli della 
flora intestinale (Merril CR. et al., 2003). Inoltre, essendo dei parassiti obbligati hanno 
il vantaggio di presentare una crescita esponenziale che è direttamente 
proporzionale alla carica microbica presente durante l’infezione (Merril CR et al., 
1996), per contro hanno come svantaggio quello di avere un’ emivita breve e di 
essere instabili senza il loro ospite. Per ovviare a questo loro limite, nasce l’esigenza 
di realizzare un sistema (scaffold) che sia in grado di stabilizzare il fago, aumentarne 
l’emivita  e  veicolarlo  all’interno delle cellule eucariotiche.  
Una molecola ideale, con le suddette caratteristiche, potrebbe essere l’Idrossiapatite 
Ca5 (PO4)3 (OH): raro minerale di forma esagonale appartenente al gruppo 
dell’apatite. Questi nanocristalli presentano eccellenti proprietà biologiche (Roveri N. 
et al., 2006; Barroug A. et al., 2003), non sono tossici, non inducono la risposta 
infiammatoria (Iafisco M. et al., 2008) ed hanno un’elevata attitudine a 
stabilizzare/veicolare molecole e farmaci bioattivi (Akawa T. et al., 1999).  
 
Scopo della tesi 
La scoperta degli antibiotici nel 1928 ha salvato milioni di vite e alleviato la 
sofferenza di molti pazienti. Ora, quasi 90 anni dopo, siamo nell'era "post-antibiotica", 
in cui diverse infezioni batteriche non possono essere trattate con successo perché 
anche i farmaci più potenti sono ormai inutili. Epidemie infettive causate da batteri 
resistenti sono numerosissime, la più conosciuta è la pandemia globale di infezione 
da Staphylococcus aureus resistente alla meticillina (MRSA) (Moran GJ. et al., 
2006). Il sistema sanitario degli Stati Uniti investe circa $ 34 miliardi ogni anno per 
sradicare questo patogeno (Filice GA. et al., 2010), più letale di malattie come l’ 
HIV/AIDS, morbo di Parkinson, e l'enfisema (Klevens RM. et al., 2007). Negli Stati 
Uniti ed in altre parti del mondo è comune l’utilizzo di antibiotici in agricoltura e negli 
allevamenti come promotore di crescita (Levy SB. et al., 2002). Questo uso 
inappropriato contribuisce all'aumento della resistenza agli antibiotici sia per i Gram-
negativi che per i Gram-positivi. La produzione di antibiotici non è di rilevante 
interesse economico per le aziende farmaceutiche in quanto, i batteri hanno la 
capacità di sviluppare resistenza agli antibiotici velocemente, rendendo il loro uso 
sempre meno funzionale. In questo studio si propone la possibilità di utilizzare 
batteriofagi o peptidi antimicrobici per contrastare le infezioni batteriche, in campo 
farmaceutico come nuova terapia e nel campo agroalimentare per ridurre l'uso di 
conservanti sintetici e contemporaneamente aumentare la shelf-life dei prodotti. 
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Disegno sperimentale 
Lo studio è stato articolato in quattro fasi: 
 
1. Identificazione, produzione e valutazione dell’attività antimicrobica di PAP3 
Negli ultimi anni, sono state scoperte diverse proteine che mostrano attività 
antibatterica non legata alla loro funzione primaria. Queste proteine sembrano agire 
come vettore di peptidi antimicrobici criptici, che potrebbero essere rilasciati dalle 
proteasi umane o batteriche. I peptidi antimicrobici criptici sono spesso situati 
all'estremità N-o C-terminale della proteina, quindi durante il processo di maturazione 
possono essere liberati. Per identificare rapidamente peptidi antimicrobici criptici, il 
Dr. Notomista E. (Dipartimento di Biologia, Università di Napoli Federico II), ha 
sviluppato un sistema di previsione che correla le caratteristiche strutturali dei 
CAMPs con le loro proprietà antimicrobiche. Il sistema di previsione è stato utilizzato 
per analizzare le proteine secrete umane depositate negli appositi database. Con 
questa analisi sono state identificate come potenziali peptidi antimicrobici le porzioni  
N-terminale dell’isoforme A3, A4 e A5 del pepsinogeno umano. Il pepsinogeno è 
costituito da una singola catena polipeptidica di peso molecolare di circa 42 000 Da  
contenente tre legami disolfuro ed un punto isoelettrico di 3.7. Esso è costituito da tre 
regioni: un peptide segnale (circa 15-16 aa), un segmento di attivazione (circa 47 aa) 
e la parte attiva dell'enzima (326 aa). Dall'allineamento delle sequenze 
amminoacidiche è emerso che le tre isoforme differiscono per un amminoacido:  
l'isoforma A3 ha un residuo di lisina (K43), mentre le isoforme A4 e A5 hanno un 
residuo di acido aspartico (E43). Pertanto, il pro-peptide dell’ isoforma A3 del 
pepsinogeno (PAP3) ha due cariche positive in più rispetto alle isoforme A4 e A5. 
Questa caratteristica rende l’isoforma A3 particolarmente interessante per questo 
studio. Per la produzione di PAP3 è stato  utilizzato un sistema di espressione 
procariotico (E. coli) che rappresenta una valida alternativa alla sintesi chimica. Per 
evitare che il peptide antimicrobico potesse risultare nocivo per le cellule di E. coli, 
durante la fase di sintesi (Li Y. et al., 2009), abbiamo scelto di esprimere il peptide 
PAP3 come proteina di fusione posizionandolo al C-terminale dell’onconasi 
(ribonucleasi)  di rana. Per separare il peptide dall’onconasi è stato necessario 
interporre fra le due parti una sequenza GTGDP linker, che come è noto in 
letteratura, a 60-80°C in ambiente acido  viene degradata, generando frammenti che 
contengono al N –Terminale un residuo di Prolina. Inoltre la proteina di fusione, 
presentando una sequenza di 6 residui di istidina situati all'estremità C-terminale dell’ 
onconasi e l'N-terminale del peptide, ha permesso la purificazione della proteina 
mediante cromatografia di affinità per chelazione di metalli (IMAC). 
L’onconasi è un partner adatto per diversi motivi: i livelli di produzione risultano 
essere molto elevati come corpi di inclusione (circa 150 mg/L in brodo); nessun 
onconasi solubile può essere rilevata nelle culture (minimizzando così il rischio di 
effetti tossici del peptide); ed è una piccola proteina (104 aa) permettendo così rese 
di produzione di PAP3 più elevate. Inoltre l’onconasi estratta dai corpi di inclusione è 
solubile a pH acidi (<4) ma completamente insolubile a pH 7. Quindi  il clivaggio della 
proteina di fusione è stato effettuato a pH acido e successivamente il pH è stato 
innalzato fino a 7 utilizzando l’ammoniaca (NH3). In questo modo l’onconasi precipita 
mentre PAP3 rimane in soluzione. La proteina ricombinante è stata espressa in E. 
coli ceppo BL21DE3 attraverso 3 ore di induzione con IPTG ad una concentrazione 
finale di 0,4 mM; alla fine di questa fase, le cellule sono state sottoposte a lisi 
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meccanica mediante ultrasuoni e la porzione solubile (contenente proteine di E.coli) 
è stata rimossa mediante centrifugazione. Inoltre i componenti delle membrane 
cellulari  sono stati eliminati effettuando un trattamento con detergenti e denaturanti 
come Triton X-100 e urea. Al termine di questi trattamenti la frazione contenente 
corpi di inclusione insolubili è stata sottoposta a denaturazione e riduzione con 
guanidina-HCl 6 M e beta-mercaptoetanolo 10 mM. Il campione è stato 
successivamente centrifugato e la frazione solubile è stata purificata mediante 
cromatografia di affinità IMAC. Per distaccare l’onconasi da PAP3 è stata effettuata 
un idrolisi acida eseguita a pH 2 a 60°C e successivamente il pH è stato innalzato 
fino a 7 per allontanare l’onconasi (solubile solo in ambiente acido). Le frazioni 
(solubile e insolubile) sono state analizzate mediante SDS-PAGE al 20%. È stata 
riscontrata la presenza dell’onconasi solo nella frazione insolubile, mentre il peptide 
era presente solo in quella solubile. Il peptide PAP3 purificato è stato analizzato 
mediante cromatografia in fase inversa su colonna C18 e dal cromatogramma è stato 
possibile apprezzare la presenza di un picco principale eluito a 52.28 min, risultato 
essere PAP3 attraverso elettroforesi su SDS-PAGE al 20%. 
L’attività antimicrobica di PAP3 è stata saggiata su alcuni dei principali patogeni 
alimentari Listeria monocytogenes, Salmonella rissen, Salmonella typhimurium, 
Staphylococcus aureus, Escherichia coli. Dai risultati ottenuti è stato possibile 
osservare che PAP3 alla concentrazione di 220 µg/mL inibisce la crescita dei batteri 
in un range del  90-100%. Questi dati forniscono la prova che PAP3 (come già 
previsto da strumenti bioinformatici) è un buon peptide antimicrobico, efficace sia su 
batteri Gram-negativi che Gram-positivi. 
 
2. Isolamento, caratterizzazione e stabilizzazione dei batteriofagi  
Sono stati isolati batteriofagi dai principali patogeni alimentari: Salmonella rissen, 
Salmonella monofasica, Listeria monocytogenes, Escherichia coli e Staphylococcus 
aureus. I batteriofagi isolati sono stati caratterizzati tramite host range (range di 
attività litica), curva di crescita e MOI (Minima concentrazione di fago necessaria per 
l’ infezione del batterio). Il fago della Salmonella rissen ci ha fornito  risultati migliori: 
host range 11/14 ceppi analizzati, fase di latenza e quella di crescita rispettivamente  
di 30 e 55 min, il burst size di 54 particelle fagiche e anche ad una MOI bassa come 
0,001 è stata riscontrata una buona attività litica. Il fago della Salmonella rissen Φ1  
data la miglior risposta ai test è stato scelto per eseguire esperimenti successivi. 
Attraverso l’utilizzo della microscopia elettronica è stato possibile affermare che il 
batteriofago Φ1 fa parte della famiglia Podoviridae. Esso ha una testa di diametro  57 
± 1, 0 nm, una coda flessibile di 16 ± 2, 0 nm e la sua lunghezza totale è di 73 ± 2, 0 
nm. Il fago Φ1 ha dsDNA di 42,990 bp, costituito da 65 sequenze codoniche (CDSS) 
e contenente il 48,6% di G+C.  
Come precedentemente descritto i fagi essendo parassiti obbligati, non sono stabili 
ed hanno un’emivita breve senza il loro ospite. Per questo motivo abbiamo provato a 
stabilizzare il fago Φ1 con l’ausilio dell’idrossiapatite (HA).  
 
I nanocristalli di idrossiapatite biomimetica (HA) [Ca5 (PO4)3 (OH)] sono stati 
precipitati da una soluzione acquosa di (CH3COO) 2Ca mediante lenta aggiunta di 
H3PO4, mantenendo costante il pH a 10 per aggiunta di (NH4) OH (Palazzo B. et al., 
2009). Per  produrre HA con il rapporto stechiometrico Ca/P di 1.67, la sospensione 
di Ca (CH3COO)2 e la soluzione di H3PO4 utilizzati erano rispettivamente 83 e 50 
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mM. La miscela di reazione è stata agitata a 37°C e dopo 24h è stata lasciata in 
condizioni statiche per 2 ore per permettere la deposizione della fase inorganica. 
Quest’ultima è stata lavata ripetutamente con acqua e liofilizzata a -60°C sotto vuoto 
(3 mbar) per 12 ore. L'idrossiapatite biomimetica prodotta è risultata simile a quella 
riscontrata nel corpo umano. Essa rivela una morfologia piastriforme, con lunghezza, 
larghezza e spessore di circa 110 ± 5 nm, 20 ± 3 nm e 8 ± 2 nm. L'elevata reattività 
dell’ idrossiapatite è attribuita alla sua superficie amorfa, ed alla sua elevata area 
superficiale di circa 110 m2/g, che è solo di poco inferiore a quella dei nanocristalli 
biologici (120 m2/g). Quando i nanocristalli di HA sono a pH 7,4 mostrato un 
potenziale zeta di 20,5 ± 1,5 mV, questo valore è attribuito alla loro superficie 
amorfa. Gli studi condotti mediante spot test, hanno evidenziato una maggiore 
stabilità del complesso fago-idrossiapatite rispetto al solo fago infatti dopo diversi 
mesi conservato a + 4°C, il fago complessato con l’idrossiapatite mantiene costante il 
suo titolo espresso in PFU/mL. Inoltre il complesso resta attivo anche in ambiente 
acido, per questa ragione, potrebbe essere idoneo per combattere le infezioni nel 
tratto gastro-intestinale. 
 
3. Test per valutare la citotossicità  
Sulle cellule del carcinoma del fegato (HepG2) sono stati effettuati due test distinti 
(MTT e LDH) per valutare la citotossicità del peptide PAP3, del fago Φ1, del 
complesso e dell’idrossiapatite. Il test MTT (bromuro di 3-(4,5-dimetiltiazol-2-il)-2,5-
difeniltetrazolio) ha dimostrato che PAP3 è tossico per le cellule eucariotiche, mentre 
gli altri trattamenti non influenzano la vitalità cellulare: le cellule sono risultate vitali 
anche dopo 72 ore dal trattamento. LDH test ha evidenziato una bassa produzione 
dell’enzima lattato-deidrogenasi per ciascuna condizione sperimentale fino a 72 ore, 
tranne per PAP3, il quale ha determinato un significativo incremento di LDH. Con 
questi risultati è possibile affermare che il fago Φ1, il complesso e l’idrossiapatite non 
comportano nessuno stress alle cellule eucariotiche del carcinoma del fegato, mentre 
PAP3 è risultato citotossico.  
 
4. Attività antimicrobica nelle cellule eucaristiche e nella carne  
Per valutare l’attività intracellulare  sono stati effettuati due esperimenti distinti. In uno 
le cellule sono state infettate con Salmonella rissen, trattate con gentamicina   e solo 
dopo 3h di incubazione a 37°C, sono stati effettuati i trattamenti con il fago Φ1, il 
complesso e la sola idrossiapatite. Nel secondo esperimento, l’infezione con la 
Salmonella e i diversi trattamenti sono stati effettuati contemporaneamente. Dopo 
18h di incubazione a 37°C, le cellule di entrambi gli esperimenti sono state lisate ed il 
lisato è stato spottato su piaste XLT4. I risultati del primo esperimento evidenziano 
una efficace attività antimicrobica solo per il complesso (Φ-HA), mentre il fago e 
l’idrossiapatite da soli non hanno determinato nessuna riduzione della carica 
microbica. Dai risultati ottenuti dal secondo esperimento (dove è stata effettuata 
l’infezione contemporaneamente ai trattamenti), è stato possibile valutare che anche 
il fago come il complesso (Φ-HA), ha determinato una sostanziale diminuzione della 
crescita batterica. Con questi risultati è possibile sostenere che il fago da solo non ha 
la capacità di entrare nelle cellule eucariotiche e solo quando è veicolato 
dall’idrossiapatite o dal batterio (nel nostro caso la Salmonella rissen) riesce ad 
uccidere i batteri intracellulari. Invece il complesso (Φ-HA),  è capace di entrare 
all’interno delle cellule eucariotiche grazie all’azione dell’idrossiapatite, che tramite un 
  
 
 
 
 
6 
 
meccanismo di endocitosi determina l’ingresso del fago nel citoplasma delle cellule 
eucariotiche (Bauer I.W. et al., 2008). 
Per  saggiare l’attività antimicrobica negli alimenti, del fago Φ1, del complesso (Φ-
HA),  e dell’idrossiapatite, un campione di carne da 250 gr è stato suddiviso in 5 
porzioni uguali, di cui 4 sono state infettate con 20 ml di Salmonella rissen ed 
incubate a temperatura ambiente per un corretto fissaggio batterico. La quinta 
porzioni è stata trattata solo con 5 ml di PBS (controllo negativo). Dopo 30 minuti di 
incubazione 3 delle 4 porzioni infettate sono state trattate rispettivamente con il fago 
Φ1, il complesso e l’idrossiapatite, mentre la quarta non ha subito nessun 
trattamento (controllo positivo). Tutti i campioni sono stati conservati a 4°C per 7 
giorni e analizzati ad intervalli regolari di 24h. Ad ogni intervallo di tempo, 5 gr di 
carne (prelevati da ogni da ogni campione) sono stati omogeneizzati in 45 ml di 
acqua peptonata (PW) allo 0,1% utilizzando lo Stomacher 400 Circulator, Seward 
Ltd. Successivamente 100 µl di campione sono stati piastrati su XLT4 agar ed 
incubati a 37°C per 24h. L’efficacia dei singoli trattamenti è stata valutata mediante 
conta delle CFU/gr. Le colonie di Salmonella nel campione trattato con il fago sono 
state ridotte di 0.3 log CFU/gr mentre il campione trattato con l’idrossiapatite aveva la 
stessa carica di Salmonella del controllo positivo 5.5 log CFU/gr. Grazie al 
complesso (Φ-HA), invece,  la carica microbica nella carne è stata ridotta di 3 log 
CFU/gr. 
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Conclusioni 
L’ antibiotico resistenza è uno dei maggiori problemi di interesse socio economico 
che coinvolge il mondo scientifico e il mondo farmaceutico. Questo problema, riflette 
l'uso inadeguato di questi farmaci “miracolosi” e la mancanza di nuove terapie 
antimicrobiche in grado di tenere il passo con l'evoluzione dei batteri. Interventi 
legislativi per modulare l'uso di antibiotici sono all'orizzonte, ma per risolvere 
veramente questa crisi farmacologica sono necessari nuovi approcci scientifici. In 
questo lavoro di dottorato sono state proposte due alternative agli antibiotici: i peptidi 
antimicrobici e i batteriofagi. 
Il peptide antimicrobico utilizzato (PAP3) è stato identificato dal sistema di previsione, 
aveva una buona attività litica in vitro contro vari agenti patogeni, ma è risultato 
tossico per le cellule eucariotiche anche a bassa concentrazione. Per questo motivo 
non è stato utilizzato per ulteriori esperimenti. 
I batteriofagi sono stati isolati con successo da diversi agenti patogeni alimentari 
come Salmonella typhimurium, Salmonella rissen, Listeria monocytogenes, ed 
Escherichia coli. Il fago Φ1 (isolato da Salmonella rissen), è stato scelto per ulteriori 
studi in vista del suo ampio host range e della sua buona attività litica. Utilizzando la 
microscopia elettronica e analizzando la sequenza di DNA, il fago Φ1 è stato 
classificato nella famiglia Podoviridae e il suo genoma è risultato diviso in tre parti 
(preearly, early, and late regions) come il fago T4. 
Il problema è che i fagi hanno una breve emivita e non possono essere utilizzati 
contro infezioni intracellulari, poiché non sono in grado di penetrare la membrana 
delle cellule eucariotiche. Inoltre, i fagi non sopravvivono in ambienti a pH acidi come 
quello dello stomaco e la loro vitalità può essere compromessa quando impiegati 
durante le fasi di lavorazione e di conservazione degli alimenti (Colom J. et al., 
2017). Questi problemi sembrano risolvibili complessando i fagi con l'idrossiapatite: il 
complesso risulta essere stabile e capace di attraversare la membrana delle cellule 
eucariotiche. Inoltre, il Φ-HA è in grado di sopravvivere per più di 24 ore a pH 
estremamente acidi e di controllare l’infezione da Salmonella nella carne. Sulla base 
dei risultati ottenuti, si ritiene che  il complesso (Φ-HA) possa essere considerato uno 
strumento biotecnologico efficace per il trattamento e/o la prevenzione delle infezioni 
batteriche.  
Studi futuri riguarderanno l’analisi chimica-fisica per caratterizzare l’interazione tra il 
fago e l’idrossiapatite e un eventuale utilizzo dello stesso complesso associato ai 
peptidi antimicrobici 
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SUMMARY 
The inappropriate and excessive use of antibiotics in medicine and agriculture led to 
the development of antibiotic resistant bacteria as shown by the data presented  by 
the ECDC (European Centre for Prevention and Disease Control) and the HI (Health 
Institute). The development of new therapeutic agents is necessary to cope with this 
emergency. The characteristics demanded to new antibacterial drugs are greater 
selectivity and a different mechanism of action compared to traditional drugs in use. 
The peculiar properties of peptides and phages make their use attractive to counter 
the problem of antibiotic resistance. The CAMPs are widely distributed in nature and 
differ in terms of length, primary and secondary structures, but they all have the   
characteristics of being cationic and amphipathic. The CAMPs have as " target” the 
bacterial cell membrane. This structure is highly conserved among bacteria and its 
reorganization would be highly expensive and difficult to realize. 
Bacteriophages are viruses that specifically infect bacterial cells. They do not harm 
the natural flora of the human host when used as antimicrobial agents. In this study, 
we used the antimicrobial peptide PAP3 (A3 isoform of human pepsinogen) and the 
phage Φ1 (isolated by Salmonella rissen).  
PAP3 displays a strong antimicrobial activity against several bacterial species (at the 
concentration of 220 µg/mL inhibits 90%-100% of bacteria). Unfortunately, PAP3 is  
toxic for eukaryotic cells, even at low concentration and for this reason it has not 
been  studied further. On the contrary, the phage Φ1, - isolated and characterized in 
the course of this study - is a good antimicrobial agent. To the same extent of all the 
other phages, Φ1 is species-specific, is not toxic to eukaryotic cells and one single 
dose of phage is sufficient to control bacterial infection. To date, no phage 
preparation for intracellular pathogens is available. In this study – for the first time – it 
was tested the use of hydroxyapatite as a vehicle to carry Φ1 inside the eukaryotic 
cell. It was shown that hydroxyapatite carries the phage inside eukaryotic cells and 
does it without damaging the cells. The hydroxyapatite, Ca5 (PO4)3 (OH), is a rare 
mineral of the apatite group. It has the shape of a hexagonal prism and serves as 
protective  scaffold and as carrier of bioactive molecules. Our results show that the 
complex (phage-hydroxyapatite) is more stable than phage alone, is active at pH 2 
and is  a good agent to reduce bacterial contamination in the food. 
Based on our results, we  believe that the use of bacteriophages complexed with 
hydroxyapatite  represents a promising biotechnological approach to treat /to prevent 
bacterial infections in several areas. 
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1. INTRODUCTION 
 
1.1 Antibiotic 
Antibiotics are natural or synthetic substances, which can control bacterial infections 
(bactericide antibiotics) or inhibit their growth (bacteriostatic antibiotics). Based on 
their spectrum of action, antibiotics can have a broad spectrum (when are active 
against Gram positive and Gram negative bacteria) or narrow-spectrum (in the case 
of molecules active against a restricted number of bacterial species). Before the 
discovery of this important class of drugs, many "harmless" disease led to death 
(seasonal virus, pneumonia, septicaemia, tuberculosis). The birth of antibiotics dates 
back to many centuries ago. Greeks and Egyptians took care of febrile infections with 
natural substances, and in 1700 moulds began to be used. In 1868 Pasteur began 
the "fight" against bacteria. In 1900 Paul Ehrlich experimented a compound effective 
against the syphilis bacterium. In this research climate in 1928, the English 
microbiologist Alexander Fleming noted that a mould contamination destroyed a 
bacterial culture completely. Fleming identified the mould as belonging to the 
Penicillium notatum species. In the 40s this wonder drug was spread all over the 
world and Fleming won the Nobel Prize for medicine in 1945 (Blaser MJ. 2016). In 
the following years different chemical researchers discovered other molecules with 
antibacterial activity and their efforts greatly improved the quality of life of humankind. 
Inappropriate and excessive use of antibiotic led to the development of resistant 
strains (Pamer EG. 2016). In 1952 a multidrug-resistant Shigella strain (tetracycline-, 
streptomycin- and sulphonamides-resistant) was isolated. In 1959 the multiple 
resistance to these antibiotics was transferred to E. coli. Today antibiotic resistance 
an increasingly important medical problem. The antibiotic-resistance assumes great 
importance also in the food industry. The EFSA (European Authority for Food Safety) 
has reported that resistance to nalidixic acid in Salmonella enterica has grown from 
13% to 15%. Microorganisms have several alternatives to avoid the lethal action of 
antibiotics (Sibhghatulla S. et al., 2015) (Fig.1) through: 
a) production of enzymes able to inactivate antibiotics (many pathogens produce b-
lactamases, this enzyme hydrolyses the lactam-ring b, destroying the antibacterial 
activity of antibiotics); 
b) alteration of the permeability of the casing (in this way the drug cannot penetrate 
the bacterial cell); 
c) modification of the target (antibiotic target is modified by replacing single amino 
acid, acquisition of a gene and methylation); 
d) active transport systems (through this system the antibiotic is transported outside 
of the bacterial cell); 
e) alternative metabolic pathways. 
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Figure 1: Resistance mechanisms of bacteria 
(http://www.cell.com/cms/attachment/2002995576/2011441548/gr1.jpg). 
 
 
The development of new therapeutic agents is necessary to cope with these 
emergencies. The characteristics demanded to the new antibacterial drugs are 
greater selectivity and a different mechanism of action compared to traditional drugs 
in use. The antimicrobial peptides and bacteriophages could be the  answer to this 
emergency. 
 
1.2 Antimicrobial peptides 
The cationic antimicrobial peptides (CAMPs) are small molecules widely distributed 
in nature, synthesized by organisms belonging to the plant and animal kingdoms. 
The CAMPs derive from a pro-peptide of approximately 60-170 amino acids and are 
then released into the mature form after the action of specific proteases that produce 
amino acid sequences of a variable number of residues (10-50) (Gautier M.F. et al., 
1994). They are different in terms of length, primary and secondary structure, but are 
both cationic and amphipathic.  These features allow the peptides to interact with the 
cell membrane, forming ion channels or pores or dissolving the membrane, like  
detergents (Rinaldi A. C. et al., 2002). The antimicrobial peptides constitute the first 
defence line of the organisms against a large variety of external agents (Boman H.G. 
2000) and in higher organisms link the mechanisms of innate and acquired immunity 
(Vizioli J. et al., 2002). The CAMPs directly destroy pathogens (Scott MG. et al., 
2007), but they modulate also the response of the immune system, activating 
chemotaxis, regulating cytokine production and stimulating the immune system cells, 
such as monocytes and antigen-presenting cell (APC). Furthermore, they are also 
able to modulate the release of histamine and enhance angiogenesis, accelerating 
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the healing of wounds (Salzet M. et al., 2002; Chen Q. et al., 2004). The innate 
immunity peptides rapidly respond against infectious agents (Tossi A. et al., 2002). In 
mammals, they act earlier than the antibody response or cell-mediated immunity, 
CAMPs are able to kill bacteria within 20 minutes from treatment (Piers KL. et al., 
1994). Insects under normal conditions show a low level of antimicrobial peptides, 
but upon exposure to pathogens peptides production rapidly increases (Hoffmann JA 
et al., 1996; Levy F. et al., 2004).  
Some antimicrobial peptides exert different functions. For example, the puroindoline  
(antimicrobial proteins of wheat belonging to defensins family) act against different 
types of pests and mushrooms (Dubreil L. et al., 2002; Capparelli R. et al., 2005; 
Capparelli R. et al., 2006), and they also control the wheat grain hardness (Giroux 
MJ. et al., 1998). CAMPs act on Gram-positive, Gram-negative bacteria, and also on 
viruses, fungi (Lai Y. et al., 2009) and cancer cells (Tomasinsig L. et al., 2006; 
Hoskin DW. et al., 2008). The action of antimicrobial peptides depends on the amino 
acid sequence (Zhao H. et al., 2002), and from lipids that make up the bacterial 
membrane (Brian M. et al., 2010). The net charge of antimicrobial peptides is directly 
correlated with their attraction / interaction with the bacterial membrane. In fact, a 
cationic antimicrobial peptide, which has a net positive charge at physiological pH  
(Shai Y. et al., 1996; Oren Z. et al., 1998; Maher S. et al., 2006), can easily interact 
with the negatively charged bacterial surface (Brogden K.A. et al., 2007). In contrast, 
the interactions of cationic peptides with mammalian cell membranes are significantly 
weaker because they are rich in phospholipids zwitterionic (free of charge), such as 
phosphatidylethanolamine, phosphatidylcholine and sphingomyelin (Yeaman M.R. et 
al., 2003). Moreover, the presence of cholesterol in the cell membrane of mammals, 
reduces activity of the peptides (Matsuzaki K. et al., 1996).  The bacteria hardly 
develop resistance to the antimicrobial peptides (Thevissen K. et al., 2000; Boman 
HG. et al., 2003; Levy F. et al., 2004) because the CAMPs  act against the bacterial 
membranes with different mechanisms respect the common drugs. Three important 
interaction models were developed: the model "barrel-stave", "carpet" and "toroidal 
pore" (Fig.2). 
 
 
Carpet model: In this model, the peptide is positioned parallel to the double layer of 
membrane phospholipid (Bechinger B. et al., 1999), with the hydrophobic groups in 
contact with the heads of anionic phospholipids of the bacterial membrane and the 
hydrophilic facing outward. These interactions determine the rupture of the bacterial 
membrane (Oren  Z. et al., 1998; Shai Y. et al., 2002). 
 
 
Barrel stave model: The peptides are arranged perpendicularly to the bacterial 
membranes, with the hydrophobic groups toward the anionic heads of the 
phospholipids. In this case the peptide kills the microorganisms by puncturing the 
bacterial membrane. 
 
 
Toroidal pore model: it combines the actions of barrel-stave and carpet model 
(Yang L. et al., 2001). The peptides are arranged on the bacterial membrane as 
occurs in the carpet model, after they are inserted perpendicularly into bacterial 
membrane causing deformation (Matsuzaki K. et al., 1996).  
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Figure 2: Model "barrel-stave", "carpet" and "toroidal pore 
(https://www.weizmann.ac.il/Biomolecular_Sciences/Shai/sites/Biological_Chemistry.Shai/files/carpet
model.png). 
 
 
At high concentration, many CAMPs have a detergent action regardless of their 
mechanisms at low concentration (Sato H. et al., 2006). 
Another mechanism of action may involve the interaction of peptides with intracellular 
targets (Yeaman M.R. et al., 2003). Intracellular mechanisms of action are able to  
inhibit the synthesis of DNA, RNA and proteins, block the molecular chaperone, 
induce the production of ROS (reactive oxygen species) and inhibit breathing. These 
mechanisms may act independently or in synergy with membrane permeabilization 
events (Park SH. et al., 1998).   
The antimicrobial peptides are able to interact with other molecules, whether they be 
conventional antibiotics or other antimicrobial peptides (Hancock RE. et al., 2000; 
Rosenfeld Y. et al., 2006; Scott MG. et al., 1999). CAMPs might have different 
isoforms with different antimicrobial activities. Production of CAMPs with similar – but 
not identical - structures is a strategy of natural selection to increase the spectrum of 
this class of antimicrobial molecules. 
 
1.3 Pepsinogen 
In recent years numerous eukaryotic proteins were described, which behave as  
antimicrobial peptides vectors (D’Alessio G. 2011). When these proteins are in 
contact with proteases (bacterial and\or host), release peptides that function as 
CAMPs. An example is the pepsinogen; this protein is the precursor of the pepsin 
and it belongs to aspartic protease family. The pepsinogen is a single polypeptide 
chain of about 42 000 Da. It contains three disulphide bonds and has an isoelectric 
point of 3.7. The proteases are activated by the acid pH of the gastric lumen and 
have the function to digest proteins through the hydrolysis of peptide bonds. Pepsin 
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has a symmetry lobe and the active site is located between the two lobes (Fig.3). 
This enzyme cut hydrophilic or aromatic amino acid in 8 residue sequences.  
 
 
 
 
 
Figure 3: Active site of Pepsin  
(http://readanddigest.com/wp-content/uploads/2012/11/active-site.jpg). 
 
 
The amino acid sequence of pepsinogen has highlighted three regions: a signal 
peptide (about 15-16 aa), an activation segment (approximately 47 aa) and the active 
part of the enzyme (326 aa) (fig.4). The signal peptide is involved in transport 
mechanisms and has a highly hydrophobic sequence, which is removed during the 
synthesis of the pepsinogen. The activation segment (propeptide) has many basic 
residues and few acidic residues; on the contrary the pepsin (enzyme) is rich in 
acidic residues. The positive charge of lysine and arginine of the propeptide are 
essential to balance the negative charge of the carboxyl groups present in the 
pepsin. In fact, the molecule of pepsinogen is stabilized by electrostatic interactions, 
hydrophobic and hydrogen bonds. The activation of pepsin is obtained by breaking 
the peptide bond between the propeptide with pepsin (L47-V48). In this way, we have 
the enzyme activation and the release of the amino-terminal peptide of 47 aa 
(Kageyama T. 2001). 
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Figure 4: Pepsinogen activation 
 (https://i.stack.imgur.com/tx3xF.png). 
 
 
There are seven different types of pepsinogen. By electrophoresis on acrylamide gel, 
these were numbered Pg1 to Pg7, in order of decreasing mobility. The seven 
members were classified into two immunologic groups: pepsinogen I (sPGI) or 
pepsinogen A (PGA) [comprising fractions Pg1-pg5] and pepsinogen II (sPGII) or 
pepsinogen C (PGC) [including the PG6-Pg7] fractions. The sPGI is exclusively 
produced by the peptic cells; the sPGII is produced by the glands of the whole gastric 
mucosa and in small quantities from the glands of Brunner located in the duodenum. 
Pepsinogen C is present also in the lung, pancreas and prostate. The amino acid 
residues present around the catalytic site are stored in different types of pepsinogen, 
but the amino acid sequences of the pro-peptides are different. However, they all 
have positive charge, crucial to the stabilization of pepsinogen. Two peptides were 
isolated from the stomach of Rana catesbeiana that showed a high antimicrobial 
activity on a broad spectrum of microorganisms (Minn I. et al., 1989). These peptides 
are derived from N-terminal of pepsinogens A and C. The experimental results 
reported by Minn, together with results obtained from prediction system of Dr 
Notomista E, suggest that the peptides derived from pro-sequence of pepsinogens 
may play a role in antimicrobial functions of the gastric mucosa of vertebrates. The 
pro-peptide of 47 aa presents at the N-terminal isoform A3 of Human pepsinogen 
(PAP 3) was produced and tested in this work.  
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1.4 Bacteriophage 
In 1896 Hankins noted the existence of "antibacterial agents" in the Ganges 
(Sulakvelidze A. et al., 2001), and Jumna rivers. the first scientific experiments on 
bacteriophage were carried out by Felix d'Herelle (a researcher at the Pasteur 
Institute in Paris) in 1917. He proved the antibacterial activity of bacteriophages on 
Shigella dysenteriae in rabbits and chickens. After these preliminary results, he 
decided to call these antimicrobial agents phages "eaters” of bacteria. In 1930  
d`Herelle founded the Institute for the Study of Bacteriophages in Georgia, where still 
today phages are regularly used to control bacterial infections in humans (Clokie M. 
et al., 2011). Bacteriophages or phages are viruses that infect bacteria. As such they 
are obligate intracellular parasites and can multiply only within the host bacterial 
cells. These prokaryotes parasites are the most abundant form of life in the 
biosphere. Their diversity is the result of their dynamic adaptability. When phages 
infect bacterial cells, they face the host antiviral defense mechanisms and 
consequently they need to subvert these mechanisms. Phages are classified 
according to their morphology, genome, and host range. The genetic material may be 
nucleic acid RNA or DNA and the latter can be either double-or single-stranded. The 
majority of phage species have an icosahedral capsid where resides the DNA;in 
addition to the capsid, the phage has also  a collar and a tail; the tail  can have the 
plugs and fibers (Fig.5).  
  
 
                
 
                                             
Figure 5: Bacteriophage structure 
(https://explorecuriocity.org/Portals/2/article%20images/Phage.png). 
 
 
Bacteriophages with tail are classified into three families: Myoviridae, Siphoviridae, 
and Podoviridae, characterized respectively by a long contractile tail, a long non- 
contractile tail and a short tail. The bacteriophage injects his nucleic acid using a 
specific contraction mechanism. Once it was in 
jected, the phage genome can follow two routes, the lytic or the lysogenic (Fig.6) 
(Clokie M. et al., 2011). In the lytic cycle, he uses the host replication system to 
  
 
 
 
 
16 
 
produce new phage particles, that are able to lyse the host bacterial cell. At the end 
of the lytic cycle new phages could have a "mixed" DNA, viral and in part bacterial. 
Upon infection, the phage “mixed” DNA is transmitted to new bacteria. When 
integrated in bacterial chromosome, the phage is called prophage while the 
bacterium is classified as "lysogenic". The prophage confers to the host bacterium 
immunity against phages of the same type (Adams M.H. 1959). When there are 
adverse conditions, the phage splits his DNA from that of the host; it produces new 
phage particles and begins the lytic cycle (Adams M.H. 1959). 
Many viruses insert their genome into a well-defined locus of the bacterial 
chromosome. Upon excision phages often carry along also the bacterial genes 
adjacent to the insertion site (transduction). If a lytic phage infects a new bacterial 
host it can start the cycle again, or enter the lysogenic state. 
. 
 
 
 
 
Figure 6: The lytic and lysogenic cycles of bacteriophages 
(http://www.nature.com/nrmicro/journal/v4/n5/images/nrmicro1393-i1.jpg). 
 
 
Each bacterial species has several pathogenic strains that are not always susceptible 
to the selected phage. Therefore, the specificity is also a disadvantage for the phage 
since is required the rapid recognition of the bacterial cell by the phage. The host 
range (Kutter E. 2009) of the phage is restricted and limited, but this can be solved by 
creating a collection or pools of different phages, each capable of infecting a specific 
strain. Bacteriophages exclusively infect bacteria and consequently do not damage 
human, animal or plant organisms (Merril CR. et al., 2003). Moreover the phages do 
not harm the natural flora when used as an antimicrobial to control a bacterial 
infection in humans (Kutter EM. et al., 2015). An additional advantage is that phages 
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grow quickly and exponentially therefore it is possible to control bacterial infection 
with a single dose (Inal JM.  2003). These prokaryotes parasites increase when the 
microbial load is high and decrease when the bacterial concentration is low. 
Therefore, when the bacterial infection is eradicated phages die out. The in vivo 
proliferation favors topical application, because it allows the phage to infiltrate into 
the wound and reach the bacteria rapidly. The phages work fast. As a matter of fact, 
it was shown that the phage injected 45 minutes after infection by Enterococcus 
faecium is able to save 100% of the mice, and after one day all regain to full health 
(Biswajit B. et al., 2002). In addition, bacteriophages replicate at the site of infection 
where they are needed to lyse the pathogens, unlike antibiotics that "travel" 
throughout the body and do not focus on the site of infection. The identification and 
isolation of bacteriophages is a very simple process, fast and less expensive than the 
design and production of new drugs (Weber D. et al., 2000). The phenomenon of 
resistance in bacteria, known in many antibacterial applications, is present also in the 
phage therapy (Gill J. et al., 2010; Silva L. et al., 2014), but the number of bacteria 
that develop resistance to phage is about 10 times lower than the number of bacteria 
that become resistant to antibiotics (Sulakvelidze A. et al., 2001). Resistance may 
arise due to the alteration or loss of the receptors, production of modified restriction 
endonucleases that degrade the phage DNA, or to the inhibition of the phage 
intracellular development (Labrie S.J. et al., 2010). Genetic mutations affecting 
phage receptors represent the most frequent cause of bacterial phage resistance 
(Heller K.J. 1992; Labrie S.J. et al., 2010). The phages are constantly changing, so 
when bacteria become resistant, the phages evolve to infect the resistant bacteria. A 
disadvantage of bacteriophages is that, being obligate parasites, are not stable and 
have a short half-life without their host. More so, the phages can’t be used to 
eliminate the intracellular infection because the phages are not able to enter in the 
eukaryotic cells. For these reasons, in this study the phages were complexed with 
hydroxyapatite. 
 
1.5 Hydroxyapatite 
Hydroxyapatite (HA) is a rare hexagonal mineral belonging to the apatite group, 
whose chemical composition is Ca5 (PO4)3 (OH). The nanocrystals of HA exhibit 
excellent biological properties, are devoid of toxicity and do not induce inflammatory 
response (Iafisco M. et al., 2008). In the form of salts - CaCO3 (calcium carbonate), 
Ca3 (PO4)2 (calcium phosphate) and CaF2 (calcium fluoride) - HA is one of the 
constituents of the bones (Palazzo B. et al., 2009). Alteration of HA metabolism can 
lead to serious clinical consequences, such as arterial calcification, chronic kidney 
disease or osteoporosis (Zhu D. et al., 2012; Hofbauer LC. et al., 2007). HA is a 
multifunctional material, currently is used as bone void filler (Fox K et al., 2012; 
Uskokovic V. et al., 2011; Dorozhkin SV. et al., 2012), and vehicle to deliver drug in 
eucariotic cells with well determined kinetics (Roveri N. et al., 2008; Iafisco M. et al., 
2011). The hydroxyapatite, due to high affinity with proteins and  other molecules, is 
also used in various chromatographic systems (Kandori K. et al., 2000). Different 
studies have also demonstrated the stability of the interaction between the 
nanocrystals of HA and the myoglobin /alendronate, highlighting the possibility of 
using an inorganic biomaterial as a support for bioactive molecules and drugs 
(Akawa T. et al., 1999). The biomimetic HA  has a structure and composition like that 
of biological systems (Roveri N. et al., 2006) (Fig.7) and it has excellent properties in 
terms of biocompatibility, bioactivity, osteoconductivity (De Groot K. et al., 1998). 
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Figure 7: Hydroxyapatite structure 
(http://spazioinwind.libero.it/teobenedetti/ceramici_calcio_fosfati_file/image005.jpg). 
 
 
The crystals have a plate-like morphology (length and width about 110 ± 5 nm and 20 
± 3 nm, respectively) and a thickness of about 8 ± 2 nm) The high reactivity of HA 
nanocrystals is ascribed to their amorphous surface, together with their high surface 
area (about 110 m2/g), which is only slightly lower than that of biological nanocrystals 
(120 m2/g). The amorphous surface of nanocrystals is responsible for the zeta 
potential of –20.5±1.5 mV observed at physiological pH 7.4. Exciting applications of 
HA in the fields of bone tissue engineering and orthopaedic therapies have already 
been achieved (Roveri N. et al., 2006). Dimension, porosity, morphology and surface 
properties are the characteristics that need to be optimized in order to adapt 
biomimetic HA to a specific application (Tampieri A. et al., 2005). There is evidence 
that nanotechnology can sensibly improve the biological responses of HA (Barroug 
A. et al., 2003). In literature there are many works where the silicon was substituted 
by HA; and this biomaterial has shown to enhance the repair rate of bone tissue 
(Thian ES. et al., 2006; Porter AE. et al., 2004; Patel N. et al., 2002).  Furthermore, 
the hydroxyapatite reduces the adhesion of bacteria (Chen Y. et al., 2010; 
Rameshbabu N. et al., 2007; Kim TN. et al., 1998). The presence of bioactive 
molecules on the surface of biomimetic HA nanocrystals makes it possible to transfer 
information and selectively influence the biological environment. The interaction 
between proteins and different kinds of inorganic surfaces, such as HA nanocrystals, 
carbonates and phosphate, plays an important role in many applications - including 
medicine, pharmacy, nanodevices, biosensors, and bioengineering (latour RA. 2008; 
Dee KC. et al., 2003). Biomimetic represents an important tool for the design and 
synthesis of innovative materials and devices (Mann S. 1997; Sarikaya M. and Aksay 
I. 1995; Bensatude VB. et al., 2002; Sanchez C et al., 2005), which offer a unique 
approach to overcome many shortcomings in materials science (Molle P. et al., 
2005).  In this study, hydroxyapatite was used to deliver the phages into eukaryotic 
cells. Furthermore with hydroxyapatite the phages can be  stabilized and protected  
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when used as ingredient in food production or incorporated into the packaging 
system. 
 
1.6 Food Packaging 
The packaging has the role to protect the food from contamination by pathogenic 
agents and environmental factors (oxygen, moisture and heat), prolonging the shelf 
life of the product and maintaining the nutritional and organoleptic characteristics. 
Following the growing demand by consumers of natural and safe food (Kerry JP. et 
al., 2006) researchers have directed their attention to improve the quality and food 
safety. The most significant innovations in this area took place in the early twentieth 
century, when plastic, polyethylene and propylene have replaced the metal, glass 
and paper used for packaging and food storage (Wilson C. et al., 2007). In the past, 
the packaging systems functioned only as passive barriers for food protection from 
the environment, while the modern "Active packaging" system interacts with the food 
through the release of antimicrobial and antioxidant compounds (Brody A.  et al., 
2001; Lopez-Rubio A. et al., 2004). Examples of natural molecules with antimicrobial 
activity are: essential oils derived from plants (such as basil, thyme, oregano, 
cinnamon and rosemary), enzymes derived from animals (for example, lysozyme, 
lactoferrin), bacteriocin produced by microbes (nisin), organic acids (propionic acid, 
citric acid) and natural polymers (chitosan) (Brewer R. et al., 2012; Lopez-
Pedemonte TJ. et al., 2003, No. HK et al., 2007). The presence of antimicrobials in 
food packaging, as well as extending the shelf life of the food, reduces deterioration 
of the product, and the occurrence of food borne illnesses associated with microbial 
contamination (Brody AL. et al., 2008). It is very important to eliminate from the food 
the bacteria that can cause food poisoning (Ricke SC. 2003). Oils of clove, oregano, 
rosemary, thyme, sage, and vanillin are very effective (Skandamis PN. et al., 2002) 
against bacteria; this antimicrobial activity is due to the presence of phenolic 
functional groups, such as hydroxyl groups (Dorman HJD. et al., 2000). Other 
inhibitory agents against Gram-positive and Gram-negative bacteria (Mangena T. et 
al., 1999; Marino M. et al., 2001) are bacteriocin. They are small bacterial peptides 
that show strong antimicrobial activity against closely related bacteria. Nisin is a 
polypeptide produced by Lactococcus lactis spp, approved as a food additive with 
GRAS status in over 50 countries worldwide. It has a broad spectrum of activity 
against various lactic acid bacteria and other Gram-positive bacteria. Moreover, the 
effect of nisin can be enhanced by using exposure to chelating agents, osmotic 
shock and freezing, because these treatments make the cell wall of Gram-negative 
microorganisms more permeable and therefore more susceptible to the nisin (Galvez 
A. et al., 2007). The enzymes represent another group of natural compounds used in 
food packaging. Lysozyme for example, is a lytic enzyme found in foods, such as 
milk and eggs; which can hydrolyze β-1,4linkages between N-acetyl muramic acid 
and N-acetylglucosamine (Cunningham FE. et al., 1991). In industrialized countries, 
infections transmitted by food are a major public health problem, and about half of 
the episodes of disease in humans are caused by salmonella. In fact, this bacterium 
is one of the main agents of food disease transmission in humans. The transmission 
of Salmonella to humans occurs through ingestion of contaminated food of animal or 
vegetable origin. Despite controls and monitoring carried out by the authorities, the 
cases of Salmonella infection are very numerous. For this reason, it is very important 
to look for an alternative packaging system, which has as its primary objective to 
reduce the presence of salmonella in the food. 
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1.7 Salmonella  
In 1884 Georg Theodor August Gaffky isolated the agent of typhoid; after two years 
Daniel E. Salmon and Theobald Smith isolated the Salmonella choleraesuis from 
pigs. The genus Salmonella belongs to the family Enterobacteriaceae; which are rod-
shaped organisms, Gram negative, asporogenous, equipped with flagella, aerobic-
anaerobic facultative, catalase positive, oxidase negative (Fig.8). The 
Enterobacteriaceae family includes many kinds of health interest such as 
Escherichia, Shigella, Citrobacter, Klebsiella, Enterobacter, and many others. Within 
the genus Salmonella exist a large number of serotypes, distinct for the different 
composition of the somatic and flagellar antigens. Kauffmann in 1931 introduced the 
classification scheme of salmonella, accepted around the world and it is still in use. 
The genus Salmonella is divided into two species, S. enterica and S. bongori. The 
species enterica is in turn divided into six subspecies: enterica, salamae, arizonae, 
diarizonae, houtenae and indica. Today there are more than 2,400 serotypes of 
enteric species but the human infections are caused by a limited number of serovars 
(Grimont P.A.D. et al., 1997). 
In industrialized countries, infections transmitted by food are a major public health 
problem; the Salmonella and Campylobacter are the main agents of food illness. 
. 
 
 
 
 
Figure 8: Salmonella 
(http://www.journaldelenvironnement.net/mediatheque/4/7/9/000008974_5.jpg). 
 
 
 
Salmonella enterica serovar Enteritidis and serovar Typhimurium are the most 
common serovars isolated during outbreaks of foodborne in the United States and 
European Union (Finstad S. et al., 2012). 
Epidemics are frequent and can be trans-national, when products are distributed 
worldwide. The salmonellosis is subject to surveillance. The European Community 
legislation (Directive 99/2003 / EC, 2160/2003 / EC Regulation) has included it in the 
compulsory activities for the different States members. The Institute of Health 
coordinates numerous laboratories of the Italian Health Service to control of the 
Salmonella. The salmonella infection is spread by faecal-oral route through ingestion 
of contaminated food or drinks (Beuchat L.R. et al., 2002). The incubation period is 
very short; in fact, the symptoms of the disease can occur even 12 hours after 
ingestion of the bacterium. Once the ingestion of the microorganism is occurred, the 
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development of symptomatic infection depends on the number of ingested bacteria 
(the minimum infective dose is hypothesized between 102 and 103 cells), but can vary 
in the different serotypes and also depending on the host conditions. Young, elderly 
or people with reduced immune defences are more affected by salmonellosis. The 
symptoms of the gastrointestinal tract are (Tauxe RV. et al., 1998): 
- Abdominal pain; 
- Nausea and vomit; 
- Fever and diarrhea (stools of a strong dark green colour); 
- General malaise. 
The pathogenesis of Salmonella infection is complex and multifactorial. The 
bacterium colonizes the intestine, invades the intestinal mucosa and stimulates the 
migration of polymorphonuclear leukocytes (PMN) with diarrhea induction. 
In the very young or immunocompromised people, the infection may spread from the 
intestines and become systemic (Darwin KH. et al., 1999). Salmonella has several 
virulence factors, necessary to implement all stages of infection (Wallis TS. et al., 
2000) including defence systems that allow survival in acidic pH environments, useful 
to overcome the gastric barrier (Slauch J. et al., 1997); factors involved in the 
colonization of the intestine, allowing the bacterium to effectively adhere to the 
intestinal lumen cells (fimbriae type 1 and 3) (BaumL er AJ. et al.,1997) and factors 
that allow to cross the intestinal epithelium or to survive in macrophages (PhoP 
enzymes and PhoQ) (Gunn JS. et al., 2000).   Data from the Ministry of Health show 
that there are about 10-15,000 cases of non-typhoid salmonellosis each year and 
50% of food infection are given by salmonella. Salmonella enterica serovar rissen 
was recognized as one of the most common serovar among humans and pork 
production systems in different parts of the world, especially Asia (Pornsukarom S. et 
al., 2015). 
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2. AIM OF THE PROJECT 
 
The development of antibiotics in the 1928 has significantly contributed to reduce the 
mortality rate for human diseases. Now, nearly 90 years later, we are in the "post-
antibiotics" era in which several bacterial infections can’t be successfully treated 
because even our most powerful drugs are become useless. Infective outbreaks 
caused by resistant bacteria are numerous, the most known is the global pandemic 
of methicillin-resistant Staphylococcus aureus (MRSA) infection (Moran GJ. et al., 
2006). The US health care system invests $34 billion each year to eradicate this 
pathogen (Filice GA. et al., 2010) that is more lethal than pathology as HIV/AIDS, 
Parkinson’s disease, and emphysema (Klevens RM. et al., 2007). In the United 
States, a huge number of antibiotics is used each year, but only half of this is 
provided to people. The other half is used in agriculture or in the farms as growth 
promotants in food and in the animals (Levy SB. et al., 2002). This inappropriate use 
contributes to the increase in antibiotic resistance and the phenomenon affects both 
gram negative and gram positive bacteria. The development of new antibiotic is very 
slow due to market failure and regulatory disincentives. The Antibiotics resistance 
represented a serious problem for the Pharmaceutical industries because according 
to these phenomena many bacteria are able to developed the resistance to 
antibiotics making their use increasingly less effective. An antibacterial alternative 
could be the use of bacteriophages and antimicrobial peptides. In this study, we 
propose the possibility to use these antimicrobial agents against bacterial infection, in 
the pharmaceutical field as new therapy and in the agro-food field to reduce the use 
of synthetic preservatives and simultaneously increase the shelf-life of products. 
Moreover we provide a comprehensive picture regarding their advantages and 
disadvantages, the mode of action, specificity and safety. 
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3. MATERIALS AND METHODS 
 
3.1 PAP3 identification  
To quickly identify cryptic antimicrobial peptides, Dr. Notomista E. (Department of 
biology, University of Naples Federico II) has developed a system of prediction to 
correlate structural characteristics of CAMPs with their antimicrobial properties  
(Minimal inhibitory concentration). The prediction system was used to analyze human 
secreted proteins deposited into databases. The N-terminal isoforms A3, A4 and A5 
of human pepsinogen identified as potential CAMPs. These sequences were aligned 
and the N-terminal isoform A3 was chosen. 
  
3.1.1 Expression of the recombinant protein 
The cells made competent (100 µl) with CaCl2 were transformed using 20 ng of the 
recombinant plasmids pET22b(+)/ONC-DCless-His/PAP3 (provided to us by Dr. 
Notomista E.). To produce the heat shock, the competent cells were incubated on ice 
for 60 minutes and  after were incubated at 42°C for 3 minutes. Then 1 ml of LB was 
added to cells and then the sample was incubated at 37°C; after incubation, the cells 
were harvested at 4000 rpm at room temperature by centrifugation for 5 minutes; The 
precipitated cells were suspended in 100 µl of LB. The cells were plated on LB agar 
in the presence of ampicillin 100 g/mL and after were incubated at 37°C for 20 h. 
Subsequently  10 colonies were picked from the plate, and they were inoculated into 
10 mL of LB containing ampicillin 100 µg/mL. The cells were incubated at 37°C for 2h 
until OD 0.6-0.7 nm/mL. The expression of the recombinant protein was induced by 
addition of IPTG to final concentration of 0.4 mM. The induction was carried out by 
incubating the cells at 37°C for 3 h. Like negative control, one  samples has not been 
induced. After the induction phase, the cells were harvested by centrifugation at 
12000 rpm for 1 min at room temperature. 
 
3.1.2 Cell lysis and treatment of inclusion bodies 
The cells were suspended in Tris-HCl 0.1 M pH 7.4 and 20 mM EDTA and were 
lysed by sonication for 30 min. The soluble fraction of the cell lysate was separated 
from the insoluble fraction by centrifugation at 12000 rpm for 30 minutes at 4°C. The 
components of cell membranes were removed by treatment with detergents and 
denaturants such as Triton X-100 2%, Urea 2 M EDTA and 20 Mm. The inclusion 
bodies were  denatured and reduced with Guanidine-HCl 6 M and 10 mM β-
mercaptoethanol. The sample was centrifuged at 12000 rpm at 4 °C for 10 minutes 
and the supernatant was recovered and was subjected to the next step of purification 
by IMAC. 
 
3.1.3 Chromatographic IMAC 
The chromatographic resin was constituted from a hydrophilic matrix of agar to 6% 
(cross-linked) covalently bound to a chelating group. This chelating agent was loaded 
with Ni2 + ions, in this way the resin binds the histidine residues. 
5 mL of resin were centrifuged at 3500 rpm at 4°C for 15 minutes to remove the 
ethanol 20%. After the resin was washed 3 times with 30 ml of the equilibrium buffer 
then it was centrifuged at 3500 rpm at 4°C for 15 minutes and incubated with the 
sample for 20h at 4 ° C. The elution step was carried out into column, through the 
use of sodium acetate at pH 5.0 containing 0.1 M guanidine-HCl 6 M. The eluate was 
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collected in fractions of 1 ml  and the absorption was measured at 280 nm for each 
fraction. 
 
3.1.4 Determination of protein concentration 
The concentration of proteins was performed using the Bradford assay. This method 
is very fast, cheap and sensitive. It is based on the use of the Coomassie brilliant 
blue G250 (CBBG) that binds to residues of arginine, tryptophan, tyrosine, histidine 
and phenylalanine.  In acidic solution the binding of the dye Coomassie Brilliant Blue 
G-250 to proteins causes the formation of a blue product which has an absorption 
maximum at 595 nm (Bradford LW. 1976). The intensity of the absorption at 595 nm 
is proportional to the protein concentration. To determine the concentration of the 
samples was constructed a calibration line of bovine serum albumin (BSA). The 
samples were prepared in a final volume of 1 mL containing 500 µl of reagent and 
500 µl of water and absorbance was evaluated at 595 nm. 
 
3.1.5 Acid hydrolysis 
The denatured proteins in guanidine buffer/6M HCl were dialyzed in 0.1 M acetic acid 
to pH 3. At the end of dialysis, the samples were centrifuged at 12000 rpm at 4°C for 
30 min and the supernatant was subjected to acid hydrolysis. This method consists 
of three steps:  
- Acidification to pH 2 by adding HCl; 
- Incubation at 60°C for 24 h; 
- Neutralization to pH 7.2-7.4 by the addition of NH3.  
Subsequently the sample was centrifuged at 12000 rpm for 60 minutes at 4°C. In this 
way the carrier precipitates while the peptide remains in solution. The degree of 
purification was analysed by SDS-PAGE 20%. 
 
3.1.6 SDS-PAGE 
In summary the elements that make up the electrophoretic system are: 
Resolving gel is polyacrylamide solution to 15-20% that separates proteins according 
to their molecular weight. To polymerize 5 mL of Resolving were added 5 µl of 
TEMED (catalyst) and 50 µl of ammonium perosolfato 10 mg/mL (APS, radical 
initiator). Upper gel is an acrylamide solution (6%) this serves to position the samples 
on a same line and create the space in which samples are loaded. To polymerize the 
Upper gel (2.5 ml) were added 5 µl of TEMED and APS 25 µl of 10 mg/mL. The 
electrophoretic run was performed at 150 V for 60 minutes, using the running buffer 
Tris/Glycine 1X. After the electrophoretic run the gel was stained using of a 
Coomassie blue 0.2% solution (w/v) in acetic acid at 10% (w/v) and 25% isopropyl 
alcohol (p/v). Subsequently the discolouration was made in an acetic acid solution to 
7% and ethanol 25%. 
 
3.1.7 HPLC chromatography 
The chromatographic separation was performed with a  C18 column (column size 
250 x 4.6 mm; diameter of the spheres 5 µm; pore size of 280-360 Å). The analyses 
was conducted at a flowrate of 1 ml/min by performing elution gradient with two 
buffers: trifluoroacetic acid (TFA) 0.05% in water (buffer A); 0.05% trifluoroacetic acid 
in acetonitrile (buffer B). The analyses were performed using the following gradient: 
1) 10 minute isocratic elution at 5% buffer B; 2) phase of elution in a linear gradient 
from 5 to 20% of buffer B in 5 minutes; 3) elution in a linear gradient from 20 to 30% 
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of buffer B in 40 minutes; 4) Final washing of the column with 95% of buffer B. The 
spectrum of the eluted peaks was recorded between 210 and 600 nm. 
The samples to be analysed were prepared in a total volume of 2 ml in the presence 
of 5% acetonitrile and 0.05% TFA. 
 
3.2 PAP3 antimicrobial activity  
The bacteria (Salmonella typhimurium, Salmonella rissen, Listeria monocytogenes, 
Staphylococcus aureus and Escherichia coli) were grown in Muller Hinton (MH) at 
37°C until exponential phase. The samples were then centrifuged at 8000 g for 10 
minutes, washed with saline, and suspended in broth MH at approximately 106 
CFU/mL; 60 μL of inoculums were placed in a multi-well polystyrene plate from 96 
wells (bacterial concentration of 105 CFU/mL). PAP3 dissolved in AMAC was tested 
at different concentrations. The plate was incubated at 37°C for 20 hours (Romanelli 
A. et al., 2011). Microbial growth was measured  using a microplate reader model 
680 (Biorad, Hercules, CA) to 600 nm (Capparelli R. et al., 2005). The MIC value 
(Minimal inhibitory concentration)  was obtained using  the following formula: 
[(ODcontrol-ODblank)-(ODactivity-ODblank)/(ODcontrol-ODblank)] x 100. 
 
3.3 Phage isolation 
The bacteriophages were isolated from different bacterial strains: Salmonella 
typhimurium, Salmonella rissen, Listeria monocytogenes, Staphylococcus aureus 
and Escherichia coli. Gram-positive bacteria were grown in TS broth whereas Gram-
negative bacteria instead in LB broth at 37°C. When cultures reached the exponential 
growth phase, mitomycin C (1 μg/mL) was added. After 30 min the samples were 
centrifuged and bacteria were washed with LB or TS broth and incubated again for 4 
h at 37°C. The supernatants were filtered through a 0.22-μm membrane and 
screened for the presence of phages, using the spot test (Adam MH. et al., 1959).  
Individual plaques were expanded in 2 ml of broth containing the sensitive bacterial 
host (106 CFU/mL). 
 
3.3.1 Phage host range  
Gram-negative bacteria were cultured in LB broth while Gram-positive bacteria were 
grown in TS broth at 37°C until exponential phase. After 500 μl of each bacterial 
strain was individually poured into a tube containing 4 ml of 0,7% top agar. The 
suspension was transferred to a Petri dish with LB agar or TS agar layer and 
solidified. Then 10 µl of phage was spotted on lawns of different bacterial strains and 
the plates were incubated at 37°C overnight, subsequently the spectrum of infection 
was recorded. 
 
3.3.2 MOI test 
MOI of phage (Multiplicity of Infection) was determined using bacteria cultures grown 
overnight in MH. The required bacterial concentration (104 CFU/mL) was obtained by 
tenfold serial dilutions in 0.1% peptone water. The MOI range used in this test was 
between 1*10-3 to 1000, serial 1:10 dilutions of the phage were performed in SM 
buffer. The wells of 96 well microplate were filled with 100 µl  of bacterium and 100 µl 
of the diluted phage. The wells of positive and negative control contained 
respectively 100 µl of strain plus 100 µl of SM buffer and 100 µl of MH plus 100 µl of 
SM buffer. Bacterial counts were performed in triplicate for each condition tested. 
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The plate was incubated at 37°C for 18h then the optical density was measured at 
OD 600nm.  
 
3.3.3 One step growth curve 
An exponential culture (10 ml) of bacterium was centrifuged at 13800 g for 5 min at 
4°C and the pellet was suspended in 5 ml of LB (Gram-negative) or TSB (Gram-
positive). The phages were added at a MOI 1000 and allowed to adsorb for 5 min at 
RT. Then the mixture was centrifuged and the pellet was suspended in 10 ml of LB or 
TS broth and incubated at 37°C. The titer of phages was measured using the double-
layer agar technique. Aliquots (1,5 ml each) were collected at 5 min intervals over a 
time period of 90 min. Samples were diluted and were plated to determinate the 
latent and the rise period. 
 
3.3.4 Electron microscopic analysis  
Bacteria (108 cells/mL) in LB (Sigma, USA) were distributed in 24-well plate and 
incubated overnight at 37°C. After the surnatant of each well was eliminated and the 
wells were washed with PBS. The bacteria attached to the wells were fixed with 
1,25% of glutaraldehyde, 2% of paraformaldehyde and 0,1 M NaCacodylate buffer 
ON at 4°C. Following the dehydration with the ethanol 70% for 1h, 80% for 1h, 90% 
for 1h, 95% for 1h and 100% for 1h, the wells were cut and they were attached on 
the support for SEM. 
The phage stock (40 ml), containing approximately 108 PFU/mL, was purified on a 
CsCl density gradient by ultracentrifugation, and dialyzed against SM buffer  at 4°C 
overnight. Phage particles were negatively stained with 2% phosphotungstic acid (PH 
7, 2) for 5 min (the excess was removed with a filter paper). Phages were observed 
in a Philips EM 300 electron microscope. 
 
3.3.5 Phage DNA extraction 
Bacteriophage DNA was isolated using  phenol-chloroform method. Briefly, the lysate 
(40 ml) with 108 PFU/mL was centrifuged at 51,000 x g for 2 h after, the pellet was 
suspended in 1 ml of PBS. The phage suspension was treated with 12.5 mM MgCl2 
(Acros Organics, NJ, USA), 0.8 U/mL of DNase (Sigma, USA), and 0.1 µg/mL of 
RNase (Sigma, USA) (final concentrations) and incubated at room temperature for 1 
h to eliminate bacterial DNA (Nale JY. et al., 2015). Following the addition of 0.5% 
sodium dodecyl sulphate (Sigma, USA), 20 mM of EDTA (Sigma, USA) and 0.5 
mg/mL proteinase K (Fisher Scientific, Germany), it was incubated at 56°C for 2h. 
Phage DNA was extracted with an equal volume of phenol-chloroform (1:1 v/v) after 
the sample was centrifuged at 15,000 x g for 5 min. Afterwards the aqueous layer  
was treated with 0.3 M sodium acetate (Sigma, USA) and 2 volumes of ice-cold 
ethanol. After placing on ice for 10 min, the sample was  centrifuged at 21,000 X g for 
20 min, and the pellet  was dissolved in 5 Mm Tris HCl. The DNA concentration was 
analysed using a NanoDrop ND 1000 spectrophotometer and the integrity was 
checked using a 0,7% agar gel. 
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3.3.6 Phage DNA sequencing 
DNA sequencing was performed using the Ion Torrent PGM platform, yielding a total 
of 2,199,543 reads (660Mb) and an average coverage of ~13,200x. Quality control 
and trimming were carried out using in-house-implemented Python scripts, assembly 
was performed using the SPAdes software (Bankevich A. et al., 2012), and finishing 
was completed using the DraftDr software (version 1.0 CRS4; M. Orsini, unpublished 
data). Genome annotation was manually curated after a preliminary annotation 
performed by RAST ( Aziz KR. et al., 2008). 
 
3.4 Hydroxyapatite  
The nanocrystals of biomimetic hydroxyapatite (HA) [Ca5(PO4)3(OH)]  were 
precipitated from an aqueous solution of (CH3COO)2Ca by slow addition of H3PO4, 
keeping the pH constant at 10 by addition of (NH4)OH solution (Palazzo B. et al., 
2009). To produce HA with the stoichiometric Ca/P ratio (1.67), the Ca (CH3COO)2 
suspension and the H3PO4 solution used were 83 and 50 mM, respectively.  
The reaction mixture was stirred at 37°C  for 24 h, after the mixture was left in static 
condition for 2h to allow deposition of the inorganic phase. This was repeatedly 
washed with water and freeze-dried at - 60°C under vacuum (3 mbar) for 12 hours.  
 
3.4.1 Transmission electron microscopy 
The analysis were carried out using a 1200 EX microscope, linked to X-ray analysis 
detectors and a 3010 UHR operating at 300 kV (JEOL Ltd, Tokyo, Japan). Few 
droplets of the samples (in ultrapure water)  are been  deposited on perforated 
carbon foils supported on conventional copper microgrids. 
 
3.4.2 Zeta potential analysis 
To determinate the Zeta potential was used a Coulter Delsa 440, this instrument is 
able to measure the electrophoretic velocity of particles, checking the Doppler shift of 
scattered laser light simultaneously at four different scattering angles: 7.5, 15.0, 22.5 
and 30.0. For this test was used 0.05 g l-1of hydroxyapatite in 10-2 M KNO3. 
 
3.4.3 Determination of surface area 
Measurements were done using a Sorpty 1750 instrument (Carlo Erba) using N2 
absorption at 77 K (Brunauer S. et al., 1938). 
 
3.5 Complex (phage-hydroxyapatite)  
The complex was prepared by mixing the hydroxyapatite (X)  with the phages (Y) in a 
ratio 1: 1 v/v. The mixture was maintained in agitation at RT for 30’, 90’,180’,300’ and 
overnight. Then the complex was centrifuged and the pellet suspended in SM buffer. 
The amount of phage adsorbed on hydroxyapatite was determined using the double 
agar overlay method. This purpose were prepared 5 aliquots constituted by 1 ml of 
hydroxyapatite  (X) and 1 ml of phages (Y). At each time interval one aliquot was 
centrifuged at 5000 rpm for 5 ' and the pellet was suspended in 1 ml of SM buffer. 
Serial dilutions were performed for each sample and after the dilutions were tested 
using the spot test 500 µl of Salmonella rissen were added to 4 ml of Soft Agar 0.7% 
on LB agar plate and subsequently were made three spotts from 10 µl of each 
dilution. The plates were incubated at 37°C and after 24 h the lysis plaques were 
counted. 
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3.5.1 Study of the complex 
To estimate the stability of the phage and the complex in the time, we determined the 
titer using the double agar overlay method, by plating a dilution series 10-1–10-11. The 
titer was evaluated immediately after the phage and the complex preparation and at 
7 days  intervals for about 2 months. During this time, the samples were stored at 
+4°C (Mattila S. et al., 2015). 
The effect of an acidic and an alkaline pH on phage and the complex was evaluate. A 
total of 100 µl of phage free or phage with hydroxyapatite was added to test tubes 
containing 900 µl of SM buffer (pH 2, pH 4, pH 7 and pH10). After 24 h of incubation 
at 37 °C, the percentage of phages able to lyse the host bacterial cells was estimated  
(Jurczak-Kurek A. et al., 2016).  
 
3.6 Cytotoxicity trials 
 
3.6.1 MTT assay 
The human cells used in this study were the HepG2 (liver carcinoma). These were 
cultured in MEM (Minimal Essential Media), 10% fetal bovine serum, 2mM Glutamine 
+ 1% Non-Essential Amino Acids (NEAA) + 100 IU/mL penicillin, and 100 μg/mL 
streptomycin (all from Gibco, Paisley, Scotland). The cells (30000 cells/well) were 
grown in 96 well plates in volumes of 200 µl of medium and they were treated 
respectively with the PAP3 (200 μg/mL), the phage (Y), the complex (Z) and 
hydroxyapatite (X) for 24h, 48h and 72h. The wells of positive and negative control 
contained respectively 10% DMSO and PBS. The test was performed in triplicate for 
each condition tested. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) tetrazolium was dissolved in PBS, at a concentration of 5 mg/mL and a 
volume of 20 µl added to each well. After 2 hours, the medium was aspirated from 
the wells, 150 µl of isopropanol was added and the plate was incubated at 37°C for 
30`. Then the optical density was measured at 560 nm. 
 
3.6.2 LDH assay 
A lactate dehydrogenase (LDH) assay was performed using a CytoTox 96 Non-Radio 
cytotoxicity assay kit (Promega, Madison, WI, USA) at 24 h, 48h and 72h. 
 
3.7 Intracellular killing activity  
The liver cancer cells (HepG2) were distributed in 24-well plates (106 cells/well), 
incubated overnight (37°C, 5% CO2) in Minimal Essential Media (MEM) 
supplemented with 10% fetal calf serum (all from Gibco, Paisley, Scotland). 
Subsequently one part of the cells were infected with Salmonella rissen (104 
CFU/mL) for 1h. Then the medium was removed, and the cells were washed with 
PBS and incubated in MEM containing 10% fetal calf serum and gentamicin (12,5 
µg/mL) at 37°C in 5% CO2 (Capparelli R. et al., 2007). After 3 hours the cells were 
treated with the phage (Y), complex (Z) and hydroxyapatite (X) overnight. The other 
part of the cells were infected with Salmonella rissen (104 CFU/mL) and at the same 
time treated with the phage (Y), the  complex (Z) and the hydroxyapatite (X) for 1 h. 
Then the cells were treated with gentamicin like above. After 3 h the medium was 
removed, and the cells were incubated in MEM containing 10% fetal calf serum 
overnight. The cells of both experiments were lysed with Tween 20 (final 
concentration, 0.05 %) and each lysate was then serially diluted in PBS and plated 
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onto XLT4. The plates were incubated at 37°C and after 24 h typical Salmonella 
colonies were counted. 
 
3.8 Production of fluorescent complex 
The fluorescent complex was prepared mixing 1 ml of the complex (108 PFU/mL) with 
10 micro liter of fluorescein (Sigma, USA)  (6 µg/ml) overnight in agitation. 
Subsequently the mix was centrifuged at 5000 rpm for 1 min and the pellet was 
suspended in SM buffer. 
 
3.8.1 Internalization of fluorescent complex 
The HepG2 cell line was cultured at 37°C and 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum and 100 units/mL 
each of penicillin and streptomycin and 2 mmol/L glutamine. Cells were plated on 
polylysine-coated slides in 24 multi-well plates at a density of 1.0 x 105 per well. After 
24h, cells were exposed to different concentrations of fluorescent complex (10 µL of 
1:1000, 10 µL of 1:100, 10 µL of 1:10) for different time (2, 5 and 24 h). The control 
cells were treated with 10 µL of SM buffer. After treatment, the medium was removed 
from each well, cells were rinsed twice with PBS, fixed in 4% paraformaldehyde 
(PFA) for 10 min at room temperature. DAPI was used to counterstain nuclei. Slides 
were observed using a Zeiss LSM 710 Laser Scanning Microscope (Calr Zeiss 
MicroImaging GmbH). Samples were vertically scanned from the bottom of the 
coverslip with a 63 x or 40 x (1.40 NA) Plan-Apochromat oil-immersion objective. 
Images were generated with Zeiss ZEN Confocal Software (Calr Zeiss MicroImaging 
GmbH). 
 
3.9 Bacterial reduction assay on meat 
A Single colony of Salmonella rissen  was amplified in Luria-Bertani (LB) broth 
(Oxoid) at 37°C, harvested in exponential growth phase. The bacterial concentration 
required for  the experiment was  prepared by serial dilutions in 0.1% peptone water 
(PW) (Anuraj T. et al., 2015). For the test, a sample of the meat 250 g was divided 
into 5 equal parts, of which 4 were infected with 20 ml of Salmonella rissen (103 
CFU/mL) and incubated at room temperature for a correct bacterial attachment, while 
the fifth  was treated only with 5 ml of PBS (negative control). After 30 minutes, 3 of 
the four infected parts were treated respectively with the phage (Y), the complex (Z 
PFU/mL) and hydroxyapatite (X), while the fourth has not undergone any treatment 
(positive control). All samples were stored at 4°C for 7 days and analysed at regular 
intervals of 24h. For each time interval were taken 5 g from each sample and 
homogenized in 45 ml of solution 0.1% PW at 200 rpm for 1 min, using the  
Stomacher 400 Circulator, Seward Ltd. Subsequently, 100 µl of sample were plated 
on XLT4 agar and incubated at 37°C for 24h. The efficacy of each treatment was 
evaluated by counting the CFU/mL. 
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4. RESULTS  
 
4.1 Identification and  production of PAP3 
The prediction system was used to analyze human secreted proteins archived into 
databases. The N-terminal isoforms A3, A4 and A5 of human pepsinogen were 
identified as potential CAMPs. The alignment of N-terminal sequences of these 
isoforms has shown that the three peptides differed for one single amino acid: the 
isoform A3 had a lysine residue (K43), while the A4 and A5 isoforms had a residue of 
aspartic acid (E43). Therefore, the A3 isoform of human pepsinogen (PAP3) had two 
positive charges compared to A4 and A5 isoforms. This feature made the isoform A3 
particularly interesting for this study.  
PAP3 was expressed in E. coli strain BL21DE3 using the plasmid pET22b(+)/ONC-
DCless-His/PAP3 (provided  by Dr. Notomista E.). The cells were induced with IPTG 
and with SDS-PAGE 15% was proved that induced cells had expressed more 
recombinant protein than not induced cells (Fig.9). 
 
 
 
 
Figure 9: Electrophoretic analysis on SDS-PAGE15%. Lane 1: Lysozyme (14,3 kDa); Lane 2: Induced 
cells; Lane 3: Uninduced cells. 
 
To verify that the recombinant protein was expressed as inclusion bodies, an aliquot 
of the culture was subjected to lysis by sonication and the fractions (soluble and 
insoluble)  were separated by centrifugation and were analyzed on SDS-PAGE 15%. 
The recombinant protein was expressed only in insoluble form as inclusion bodies. 
This fraction was treated with detergents to remove E. coli proteins, subsequently the 
sample was analyzed on SDS-PAGE 15%. The recombinant protein was fully 
recovered while the contaminating proteins derived from E. coli were significantly 
reduced. The sample was treated  with Guanidine- B-mercaptoethanol and the 
soluble fraction was subjected to purification by affinity chromatography IMAC. The 
eluate was collected and the yield of the purification process (assessed by Bradford 
assay) was approximately 80%. The acid hydrolysis of protein ONC-DCless-
His/PAP3 was performed at pH 2 at 60°C. At the end of hydrolysis step, the sample 
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was analyzed on SDS-PAGE 20%, protein ONC-DCless-His/Pap3 was hydrolyzed 
with an efficiency of approximately 90-95%, releasing PAP3. 
The peptide purification was realized taking advantage of the different solubility 
properties between the onconase and PAP3 at different pH. The soluble and 
insoluble fractions were analyzed on SDS-PAGE at 20%, the carrier was present 
only in the insoluble fraction while the peptide was present only in that soluble 
(Fig.10). 
 
 
 
 
 
Figure 10: Electrophoretic analysis on SDS-PAGE 20%. Lane 1: Lysozyme; Lane 2: ONC-DCless-
His/PAP3 protein before hydrolysis; Lane 3: ONC-DCless-His/PAP3 protein after hydrolysis; Lane 4: 
Soluble fraction; Lane 5: Insoluble fraction. 
 
The PAP3 peptide purified by selective precipitation at pH 7 was analyzed by reverse 
phase chromatography on C18 column. The chromatogram showed the presence of 
a main peak eluted at 52.28 min. The electrophoretic analysis  of this peak proved 
that it was PAP3.  The protein concentration was determined by UV spectrometry in 
this way it was possible to estimate that by 100 mg of fusion protein ONC-DCless-
His/PAP3 was obtained about 30 mg of PAP3 peptide. 
 
4.2 PAP3 antimicrobial activity  
Antimicrobial tests carried out on several bacterial species, such as Salmonella 
typhimurium, Salmonella rissen, Listeria monocytogenes, Staphylococcus aureus 
and Escherichia coli  have demonstrated that the pepsinogen at the concentration of 
220 µg/mL inhibits 90%-100% of bacteria (tab.1). These data provide evidence that 
the PAP3 (as already predicted by bioinformatic tools) is a CAMP effective against 
Gram-negative and Gram-positive bacteria.  
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                       Table 1: Antimicrobial activity of PAP3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 Isolation of phages 
Following incubation with mitomycin (1 µg/mL for 30 min), the phages were 
successfully isolated from all strains used in this study (Salmonella typhimurium, 
Salmonella rissen, Listeria monocytogenes, and Escherichia coli). The phage Φ1 
isolated by Salmonella rissen (Fig.11), was chosen for further studies in view of its 
higher lytic activity in vitro and larger host range.  
 
 
 
                                        
                                        
                                               Figure 11: Lysis plaques of phage Φ1. 
 
 
 
 
 
 
 
 
 
 
Bacteria PAP3 
200 µg/mL 
Staphylococcus aureus  95% 
Listeria monocytogenes  93% 
Salmonella rissen  100% 
Salmonella typhimurium 100% 
Escherichia coli 97% 
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4.3.1 Host range 
The infectivity of phage Φ1 was investigated using fourteen other Salmonella 
species: S.livingstone, S.infantis, S.potsdam, S.thompson, S.mbandaka, S.winston, 
S.montevideo, S.virchow, S.ohio, S.jerusalem, S.inganda, S.wil, S. typhimurium, 
S.enteritidis. All these strains were isolated from food at the Institute Zooprofilattico 
Sperimentale Del Mezzogiorno. Eleven of the tested strains were susceptible  to 
phage Φ1 (tab.2). 
 
 
   Table 2: Phage Φ1 host range determination on different Salmonella strains. 
 
 - , Negative lysis result; + , positive lysis result. 
 
 
 
 
 
 
 
 
 
Bacteria Lytic activity 
S.livingstone + 
S.infantis + 
S.potsdam + 
S.thompson + 
S.mbandaka + 
S.winston + 
S.montevideo - 
S.virchow + 
S.ohio + 
S.jerusalem - 
S.inganda + 
S.wil + 
S.typhimurium - 
S.enteritidis + 
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4.3.2 MOI test 
The ability of phage Φ1 to reduce the growth of bacteria Salmonella rissen  was 
assessed using the phage at MOI from 1*10-3 to 1000 (serial 1:10 dilutions of the 
phage were performed in SM buffer). A decrease in OD 600nm  between the wells with 
bacteria and the wells with bacteria plus phages were observed for all the MOI 
tested. Bacterial growth inhibition was proportional to the phage dilution (Fig.12). The 
best MOI was 1000 but also to 0,001 there was a significant inhibition of bacterial 
growth. 
 
 
Figure 12: Representation of phage activity on a growing of Salmonella rissen. The absorbance is 
greatly reduced when MOI is 1000 compared to control (MOI 0). *** p<0,001. Each value are the 
mean ± DS of 3 independent experiments. Statistical analysis was performed with Student’s t tests. 
 
 
4.3.3 One step growth curve 
The one-step growth curve of phage Φ1 was determined, taking sample aliquots 
each 5 min intervals over a time period of 90 min. In this way were calculated the 
latent phase , the rise phase (Fig.13)  and the burst size. They were 30 min, 55 min, 
respectively and the burst size  was of 54 phage particles. 
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Figure 13: One step growth curve of phage Φ1. Each value is the mean ± DS of 3 independent 
experiments with 3 replicates each. Statistical analysis was performed with Student’s t tests. 
 
 
4.3.4 Electron microscopic analysis  
The phage Φ1 had the head diameter of 57 ± 1, 0 nm and the length of the flexible 
tail was 16 ± 2, 0 nm. The total length of phage was 73 ± 2, 0 nm. The electron 
microscope characteristics indicated that the phage of the Salmonella rissen (Fig.14) 
belonged to the Podoviridae family (Fig.15). Into the phage capside  there is the 
nucleic acid, it could be RNA or DNA. The phage Φ1 had DNA. 
 
 
 
 
 
                            Figure 14: Salmonella rissen observed with a SEM. Scale bars, 2 μm. 
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Figure 15: Phage Φ1 observed with a TEM. 
                                               Scale bars, 20 nm. 
 
 
4.3.5 Phage DNA sequencing 
DNA phage was extracted by phenol:chlorofom method. Using the Nanodrop the 
DNA quantity and quality were analysed. The concentration was 560 ng/µl, the purity 
was evaluated analysing the ratio 260/280 and 260/230. They were 1,76 nm and 
1,70 nm respectively. The integrity was checked using a 0,7% agarose gel (Fig.16). 
 
 
 
 
 
DNA of phage Φ1 was sequenced using the Ion Torrent PGM platform and assembly 
was performed using the SPAdes software. Genome annotation was manually 
curated after a preliminary annotation performed by RAST. The genome consisted of 
42,990 bp (Fig.17), with a G+C content of 48.6%. The genome contained 65 
predicted coding sequences (CDSs). Of those CDSs, including 7 tail shaft, 1 tail fiber, 
1 coat, 1 terminase, 1 portal, 22 other phage like protein. The remaining 32 CDSs 
encoded hypothetical proteins. No genes associated with lysogenize, toxin 
production, Salmonella virulence, or antibiotic resistance were identified, therefore 
suggesting a possible use of this phage as a prophylactic agent for the control of 
Salmonella. Further analysis, however, will be required to assign potential functions 
to the several unidentified and hypothetical gene. 
1 Lane: DNA phage 
2 Lane: EasyLadder I 
Figure 16: DNA phage extracted 
using Phenol:Chloroform method 
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Figure 17: Phage Φ1 genome representation. PHAST (PHAge Search Tool) is a web server         
designed to rapidly and accurately identify, annotate and graphically display prophage sequences 
within bacterial genomes or plasmids. Our results show that the genome investigated was catalogued 
like an intact prophage. 
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Through Blast analysis was confirmed that the phage Φ1 belonged to 
the Podoviridae family and showed 52.3% identity (determined with EMBOSS 
stretcher) to phage PHAGE_Salmon_vB_SosS_Oslo_NC_018279 it was therefore 
classified as a T4-like phage. According to the genome structure of T4 phages ( 
Miller E. et al., 2003), the bacteriophage exhibits a genome functionally divided into 
three parts: preearly, early, and late regions. The preearly region includes a large 
terminally repeated sequence. The early genes are involved in phage metabolism, 
DNA replication, and lysis, also including a tRNA gene cluster. The late genes 
encode structural proteins for mature phage particles (Fig.18). 
 
 
Figure 18: Graphic representation of gene annotation on the phage sequenced. 
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4.4 Hydroxyapatite  
The biomimetic hydroxyapatite produced in this study appears to be similar to that 
found in the human body. It reveals a plate-like morphology (Fig.19), with length, 
width and thickness of about 110 ± 5 nm, 20 ± 3 nm, and 8 ± 2 nm respectively. The 
high reactivity of  hydroxyapatite is ascribed to its amorphous surface, and to high 
surface area about 110 m2/g, which is only slightly lower than that of biological 
nanocrystals (120 m2/g). When the HA nanocrystals are at pH 7.4 they shown a zeta 
potential of 20.5±1.5 Mv, this value is ascribed to their amorphous surface. 
 
 
 
 
 
                              Figure 19: Transmission electron microscope of the  
biomimetic  hydroxyapatite. 
 
 
4.5 The complex (phage-hydroxyapatite) 
The complex was produced mixing the hydroxyapatite (X) with the phages (Y) in 
agitation. The amount of phages attached on hydroxyapatite was detected after 30’, 
90’,180’,300’ and overnight using the spot test. The results have shown that the 
phages was attached to hydroxyapatite already after 30’, but only after 24h all the 
phage in solution was absorbed. (Fig.20). 
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Figure 20: The absorbing of the phages on the hydroxyapatite after different time of the incubation 
(30’, 90’,180’,300’ and overnight). Each value is the mean ± DS of 3 independent experiments with 3 
replicates each. Statistical analysis was performed with Student’s t tests. 
 
 
4.5.1 Study of the complex 
The stability of the phage and the complex was determined doing dilution series and 
spotting them on the double agar overlay. The titer was estimated immediately after 
the preparation and each 7 days  for about 2 months. During this time, the samples 
were stored at +4°C. The title (PFU/mL) of phage after 6 weeks was decreased while 
the title of the complex was always the same (Fig.21).  
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Figure 21: The stability of the phage and the complex in the time. Each value is the mean ± DS of 3 
independent experiments with 3 replicates each. Statistical analysis was performed with Student’s t 
tests. 
 
The hydroxyapatite did not alter the specificity of the phage, in fact the complex  had 
lysate 11/14 salmonella strains analysed as phage alone. 
Phage and the complex were tested to evaluate the effect of an acidic and an 
alkaline environments on their vitality, the results showed that phage alone was 
extremely sensitive to pH 2 while the complex remained stable  (Fig.22). 
 
 
 
Figure 22: Effects of pH on the stability of  phage and complex. ** p<0,01.  Each value is the mean ± 
DS of 3 independent experiments with 3 replicates each. Statistical analysis was performed with 
Student’s t tests. 
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4.6 Cytotoxicity trials  
The human cells HepG2 (liver carcinoma) were treated respectively with PAP3 (220 
µg/mL), phage (Y), complex (Z) and hydroxyapatite (X). Using the MTT assay was 
possible to evaluate that PAP3 was toxic to eukaryotic cells, while the other 
treatments did not affect the cell viability: the cells were viable after 72 hours of 
treatment. (Tab.3). In addition, the LDH enzyme (released into the medium as sign of 
necrotic cell death) (Awad WA. et al., 2012), was evaluated after 24h, 48h and 72h 
by treatments, using the CytoTox 96 Non-Radio cytotoxicity assay kit (Promega, 
Madison, WI, USA). All treatments have induced low production of LDH (Lactate 
dehydrogenase) for up to 72 hours, except for PAP3 which resulted a significant 
increase of this enzyme (Fig.23). 
 
 
Table 3: MTT test on cells HepG2 (liver cancer cells). The cells treated respectively with PAP3 (220 µg/mL), 
the phage (Y), the complex (Z) and hydroxyapatite (X) for 24h, 48h or 72h. Each value is the mean of three 
independent experiments. 
 
 
Time (h)  
 
               Ȉ  
 
          HA  
 
         Ȉ+HA  
 
        PAP3 
 
24 
 
97% 
 
100% 
 
98% 
 
51% 
 
48 
 
94% 
 
98% 
 
96% 
 
43% 
 
72 
 
92% 
 
98% 
 
94% 
 
38% 
 
 
 
 
 
Figure 23: LDH production in HepG2 cells treated respectively with PAP3 (220 µg/mL), phage (Y), complex 
(Z) and hydroxyapatite (X) for 24h, 48h, 72h. Positive control: control plus LDH provided by the kit. Each 
value is the mean ± DS of 3 independent experiments with 3 replicates each. 
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4.7 Intracellular killing activity  
To evaluate the intracellular killing activity, we have done two experiments using  the 
liver cancer cells (HepG2). In the first experiment, the cells were infected with S. 
rissen and after treated with gentamicin (to kill the extracellular bacteria), the phage  
(Y), the complex (Z) and hydroxyapatite (X), were added to the wells individually. In 
the second experiment the cells were infected with Salmonella rissen and treated 
with phage (Y),  complex (Z) and  hydroxyapatite (X) at the same time. Then the cells 
were treated with gentamicin like above. For both experiments, the positive control 
was represented  by Salmonella rissen infected cells. Following the incubation (24h) 
the cells of both experiments were lysed and the number of  intracellular bacteria was 
determined by plating of the lysate on XLT4 agar. In the first experiment (Fig.24 A) 
only the complex  killed  intracellular bacteria while in second experiment (Fig.24 B) 
(where the bacteria infection was done at the same time of the treatments) the phage 
and the complex have reduced the growth of Salmonella. These results demonstrate 
that phage could  not  penetrate inside eukaryotic cells and only when delivered 
inside cells by hydroxyapatite or bacteria (in this case Salmonella rissen), it was able 
to kill intracellular bacteria efficiently. 
 
 
 
Figure 24 A: Intracellular killing activity (first experiment). The HepG2 cells were infected with Salmonella 
rissen (104 CFU/mL) and after were treated respectively with the phage (Y), the complex (Z) and 
hydroxyapatite (X) for 24h. Positive control was represented by Salmonella rissen infected cells. *** p<0,001. 
Each value is the mean ± DS of 3 independent experiments with 3 replicates each. Statistical analysis was 
performed with Student’s t tests. 
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Figure 24 B: Intracellular killing activity (second experiment). The HepG2 cells were infected with 
Salmonella rissen (104 CFU/mL) and treated with phage (Y), complex (Z) and hydroxyapatite (X) at the same 
time. Positive control was represented by Salmonella rissen infected cells.*** p<0,001. Each value is the 
mean ± DS of 3 independent experiments with 3 replicate each. Statistical analysis was performed with 
Student’s t tests. 
 
 
4.8 Internalization of fluorescent complex  
In order to demonstrate the internalization of complex in HepG2 cells we visualized 
the green luminescence of the fluorescent complex by Laser scanning confocal 
microscopy. Figure 25 showed that numerous green fluorescence of complex were 
internalized in the cytoplasm of the HepG2 cells already after 2h of treatment with 10 
µl of 1:1000, with an accumulation of luminescent particles after the overnight 
treatment. Nuclei were counterstained with DAPI dye (blue). No fluorescent light was 
detected in the control cells. 
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Figure 25: Confocal microscopy images of the cells control and the cells treated with the complex at 
2h, 5h, 24h. Scale bars, 20 μm. 
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4.9 Bacterial reduction assay on meat 
The data in Figure 26 show the reduction of Salmonella contamination on the meat 
after treatment with the phage (Y), the complex (Z) and the hydroxyapatite (X). The 
colonies of Salmonella in the sample treated with the phage were reduced by 0.3 log 
CFU/g while the sample treated with hydroxyapatite had the same Salmonella 
contamination of the positive control 5.5 log CFU/g. Instead the complex 
(hydroxyapatite-phage) had sensibly reduced the CFU number. In fact it was able to 
reduce Salmonella rissen of 3 log CFU/g. 
 
 
 
 
Figure 26: Bacterial reduction assay on meat. The samples of the meat were infected  with 
Salmonella rissen (103 CFU/mL) and  were treated respectively with the phage (Y), the complex (Z) 
and hydroxyapatite (X). Positive control was represented by Salmonella rissen infected meat. *** 
p<0,001. Each value is the mean ± DS of 3 independent experiments with 3 replicates each. 
Statistical analysis was performed with Student’s t tests. 
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5. DISCUSSION 
 
The inappropriate and unnecessary antibiotic use in human/veterinary medicine 
(Ament P. W et al., 2002), and agriculture (Heymann D.L. 2006) led the development 
of drug-resistant microorganisms and a fast increase in their frequency (Ferri M. et 
al., 2015). 
A few years ago, The Infectious Disease Society of America (IDSA)  confirmed that 
the resistant bacteria are and will be a risk to the United States and the rest of the 
world (Infectious Diseases Society of America. 2004). It is estimated that 30 percent 
of antibiotic prescriptions  are for respiratory tract infections and more than one half 
of which are probably viral (Llor C. et al., 2014). The antimicrobial resistance is the 
cause of severe illness and their complications, of the longer hospital stays and often 
death of the sick (Kollef M. 2008; Paul M. et  al., 2010; Livermore DM. 2012). In 
Europe occur annually 4 million infections by antibiotic-resistant germs that cause 
more than 37,000 deaths. This problem is due to the speed at which bacteria spread 
and change their genetic material. The antibiotic-resistance is the medical 
catastrophe of the third millennium (Holmes AH. et al., 2015), that threatens decades 
of scientific discoveries, and worse still, our health (Berkowitz FE. 1995). If antibiotic 
resistance continues to increase, it may become increasingly difficult to treat the 
diseases. Multifaceted interventions are needed to reduce the use of these drugs. In 
medicine is important the restriction of antibiotics only after medical examination or 
the laboratory tests, while in the farms  there is the necessity to completely eliminate 
these drugs used to promote growth in animals or to prevent infectious diseases (Llor 
C. et al., 2014). Another way could be to find new antimicrobial agents to use against 
the resistant bacteria. Excellent candidates could be the antimicrobial peptides 
(Hancock R.E. et al., 2002) an ancient group of defense molecules produced in 
several  plant, animal and invertebrate species. They attack the membrane bilayer of 
bacteria by carpet, toroidal-pore or barrel-stave mechanisms. The transmembrane 
pore formation is not the only mechanism that the antimicrobial peptides can use. 
They also inhibit nucleic-acid synthesis, alter cytoplasmic or inhibit enzymatic activity 
(Brogden KA. 2005). Thanks to the several mechanisms they can use against 
bacteria, the resistance towards these peptides is difficult to develop. Antimicrobial 
peptides have a broad range of activity against Gram-negative and Gram-positive 
bacteria, fungi, protozoa and yeast  (Bal R. 2000). They are nontoxic to eukaryotic 
cells, this is due to the difference in composition of eukaryotic and prokaryotic 
membranes (Dathe M. et al., 1999). The eukaryotic membranes are rich in 
phospholipids zwitterionic such as phosphatidylcholine, phosphatidylethanolamine, 
sphingomyelin, while in prokaryotic membranes there are phospholipids with 
negative charge (phosphatidylglycerol, phosphatidylserine and cardiolipin). The 
antimicrobial peptides are cationic and bind to membranes containing negative 
phospholipids due to electrostatic interaction. In last years, were discovered several 
proteins showing antibacterial activity not related to their primary function. These 
proteins seem to act as carrier of cryptic CAMPs which could be released by human 
or bacterial proteases. The cryptic antimicrobial peptides are often at the N-or C-
terminus of the protein, and then, after their removal, can be easily activated. In this 
study, in collaboration with Dr. Notomista E. (Department of biology, University of 
Naples Federico II) was carried out  a system of  prediction to quickly identify cryptic 
antimicrobial peptides (Pane K. et al., 2016). This one correlates the structural 
characteristics of CAMPs with their antimicrobial properties (MIC). We have analyzed 
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the human proteins deposited into databases and between these the N-terminal 
isoform A3 (PAP3) of human pepsinogen was identified like potential CAMP. This 
antimicrobial peptide (47 aa) was expressed in Escherichia coli by fusing  PAP3 to 
the C-terminus of Onconase (RNase from Rana pipiens) (Notomista E. et al., 1999). 
The Onconase (ONC) is a well suited partner for several reasons:  it can be 
expressed at high levels as inclusion bodies (about 150 mg/L); no soluble onconase 
can be detected in the cultures thus minimizing the risk of toxic effects of the CAMPs;  
it is a small protein (104 aa) thus allowing higher yields of the peptides. Moreover 
ONC extracted from inclusion bodies is soluble at acidic pH (<4) but completely 
insoluble at pH 7. Therefore if the cleavage of the fusion protein is performed at 
acidic pH and successively the pH is increased up to 7, the ONC precipitates 
whereas the majority of the CAMPs will remain in solution thus allowing a simple 
purification of the peptide (Pane K. et al., 2016). The production of peptides as fusion 
proteins also poses the problem of separating the peptide from the carrier in order to 
obtain a pure peptide. For this it was necessary to interpose between the two parts a 
GTGDP linker sequence, as it is known in the literature  the proteins containing DP 
sequences incubated at 60-80°C in acidic environment can fragment, generating 
fragments that contain at the N-terminal  a Proline residue. In addition, the fusion 
protein has a sequence of 6 Histidine residues located at the C-terminal end of 
onconase and the N-terminus of the peptide. In this way the protein was purified 
using affinity chromatography by chelation of metals (IMAC).This chromatographic 
system offers the possibility to purify proteins denatured in the presence of 
Guanidine-HCl 6 M, making this process independent from the value of the acidic pH 
needed to maintain in solution the  protein onconase-PAP3 (Pane K. et al., 2016). 
PAP3 had a good  antimicrobial activity against different pathogen bacteria. It was 
active on Gram-positive and Gram-negative bacteria, but it wasn’t used in other 
experiments because it resulted toxic for human cells.  
Another approach to the problem of antibiotic resistance is the use of bacteriophages 
(Bull J.J. et al., 2002). The idea of using bacteriophages to treat infections is old. In 
fact they were isolated for the first time by Hankins in 1896 (Topley WWC. et al., 
1929). The phages were employed for a wide variety of pathogens like 
Staphylococcus, Salmonella, klebsiella, Escherichia, Proteus and Pseudomonas and 
the  92.4% of people infected from these bacteria were cured with phage therapy 
(Slopek S. et al., 1985). Recent researches have focused on the different 
mechanisms of phage delivery. The most popular is parenteral route but also local 
phage delivery (topical, otic, oral) and inhalation had successful. Local delivery of 
phages has proven very successful especially in former Soviet country (Kuter E. et 
al., 2005).  The development of hydrogel impregnated of phages has received much 
attention, it has increased the success of wound healing. An example of commercial 
product is the Phagebio-derm which is active  against P. aeruginosa, S. aureus and 
Streptococcus spp. (Markoishvili K. et al., 2002). The development of modern 
inhalation  technologies has allowed also the use of bacteriophages to combat 
bacterial lung infections. The results suggested that phages can be nebulized and 
could be a potential approach for cystic fibrosis pulmonary infections. (Golshahi L. et 
al., 2011). The phage application as antimicrobials has focused on three family: 
Myoviridae with a big capsid (~150 nm) and contractile tail;  Siphoviridae with a small 
capsid (~50-60 nm) and a long flexible, non-contractile tail; and  Podoviridae with a 
small capsid (~50-60 nm) and a short tail (Kawa Z. et al., 2012). To enter in bacteria 
cells, bacteriophages must attach the specific receptors. This specificity (Ackermann 
  
 
 
 
 
49 
 
H-W. et al., 2007) of interaction between phage and receptor mostly influences the 
bacterial host range (Weinbauer M. G.  2004). Another crucial elements to establish if 
the phage is good as antimicrobial agent is the MOI (Ryan EM. et al.,  2011). The Φ1 
(isolated by Salmonella rissen) belonged to Podoviridae family had a good lytic 
activity host range 11/14 strains analyzed and the MOI 0,001. Furthermore the Φ1 
genome consisted of 42,990 bp, 48.6% of G+C and 65 predicted coding sequences 
(CDSs). The Φ1 genome was accorded to the structure of T4 phage. This 
bacteriophage exhibited a genome functionally divided into three parts: preearly, 
early, and late regions. The preearly region includes a large terminally repeated 
sequence. The early genes are involved in phage metabolism, DNA replication, and 
lysis, also including a tRNA gene cluster. The late genes encode structural proteins 
for mature phage particles.  
Phages are specific to the specie and not harm the natural flora when used as an 
antimicrobial to control a bacterial infection in humans (Salmond G.P.C. et al.,  2015). 
Moreover the phages grow quickly and exponentially in this way it is possible to 
control bacterial infection with a single dose (Inal JM.  2003) and when the bacterial 
infection is eradicated even phages are eliminated. Nonetheless they are obligate 
parasites and therefore without their host have short half-life and aren’t stable. 
Furthermore in contrast to antibiotics, no phage preparations for intracellular 
pathogens are available. In fact there are different works where avirulent bacteria are 
used to deliver the phages into infected cells (Broxmeyer L. et al., 2002). The 
Nanosciences and nanotechnologies have opened a new window on the 
development of nanomaterials used to administer drugs in cancer treatment, 
bacterial infections and wound healing (Kolanthai E. et al., 2017). A lot of 
nanoparticles such as carbon nanotubes, silica, metal oxide, grapheme and 
hydroxyapatite are frequently used for drug delivery (Chowdhury S. et al., 2016; 
Krishnamoorthy K. et al., 2014; Roveri N. et al., 2008). In this study the 
hydroxyapatite was chosen because it is not toxic even at high concentrations. This 
mineral (belonging to the apatite group)  binds to several biological molecules (Lelli 
M. et al., 2016).  The hydroxyapatite is similar to the constituents of human bones 
and it has good properties like biocompatibility, osteoconductivity, and degradability 
(Macchetta A. et al., 2009). For this reason he  hydroxyapatite was used to solve the 
limits of bacteriophages. Studies conducted showed a greater stability of the complex 
compared to only phage: after several months stored at 4°C, the phage complexed 
with the hydroxyapatite maintains its title expressed in PFU/ml. Furthermore the 
hydroxyapatite has allowed the entry of the phages into eukaryotic cells. In this way 
is possible to use the phage therapy also against obligate (Mycobacterium spp., 
Chlamydia spp., Rickettsia spp.) or facultative (Salmonella spp.,  Listeria spp., 
Brucella spp.) intracellular bacteria  (Silva M. 2012). 
The phages could also be used in different steps of the food chain thanks to their 
specific antimicrobial activity (Colom J. et al., 2017). For example they could be 
administered with the food or water to farm animals to prevent or to eliminate 
intestinal pathogens. The acidic conditions of the stomach limit the phage viability,  
for this is necessary an delivery system to protect  their orally administered (Ma Y. et 
al., 2008). This problem was successfully addressed by hydroxyapatite, in fact the 
complex (phage- hydroxyapatite)  was more durable than the phage alone under acid 
condition, for this reason, it could be eligible to oppose gastro-intestinal pathogens.  
Salmonella outbreaks are common in chicken, cattle, pork and turkey due to poor  
hygienic conditions  during slaughter and processing of meat (Doménech E. et al., 
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2015). It is necessary that phages remain viable when used as biocontrol agents  
against contamination on work surface, in food packaging or directly added in food to 
eliminate the bacteria. (Cooper IR. 2016). In this study, the ground meat (previously 
infected with Salmonella) was treated with the complex (phage-hydroxyapatite) and 
phage. The contamination was significantly reduced from the complex, while the 
antimicrobial action of the phage alone was not significant. This is another proof that 
the hydroxyapatite protects the vitality of the phage. 
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6. CONCLUSIONS 
 
After about 90 years from the discovery of antibiotics, we have reached a critical 
point in treating bacterial infection. Several powerful drugs that was highly efficient 
against bacteria are becoming useless. Bacteria resistant to multiple antibiotics 
threaten the global health, spoiling the benefits that were achieved with antibiotics. 
This problem reflects the inappropriate use of these drugs and the lack of new 
antimicrobial therapies able to keep up with bacterial evolution. Legislative 
interventions to modulate the antibiotic use are on the horizon, but new scientific 
approaches are necessary to resolve this pharmacological crisis (Nathan C. et al., 
2005). In this PhD work were proposed two alternative to the antibiotics:  
- Antimicrobial peptide; 
- Bacteriophage. 
The antimicrobial peptide used (PAP3) was identified by prediction system; in vitro it 
displays a satisfactory lytic activity  against several pathogens, but it results toxic to 
eukaryotic cells, already at low concentrations. In this study, the PAP3 peptide was 
not further investigated. 
Phages were successfully isolated from different food pathogens as Salmonella 
typhimurium, Salmonella rissen, Listeria monocytogenes, and Escherichia coli. The 
phage Φ1, isolated by Salmonella rissen, was chosen for further studies in view of its 
high lytic activity in vitro and large host range. Using electron microscopy and 
analyzing the DNA sequence, the phage Φ1 was classified as a member of the 
Podoviridae family. Its genome consists of three regions: pre-early, early, and late, 
thus reminding of the T4 phage. 
This study has addressed the use of bacteriophages in humans, animals and in 
different steps of the food chain. The problem is that the phages are not stable, have 
a short half-life and  cannot be used in case of intracellular infections because they 
are not able to enter the eukaryotic cells. In addition, the phages die at low pH of the 
stomach and when used during food processing and storage their viability can be  
compromised (Colom J. at al., 2017). These problems were solved successfully by 
complexing phages with hydroxyapatite. This complex is stable and able to enter 
eukaryotic cells and to remain active at pH 2. Strikingly, the complex killed the 
Salmonella artificially added to meat samples. Based on our results, we  believe that 
the use of bacteriophages complexed with hydroxyapatite  represents a promising 
biotechnological approach to treat / to prevent bacterial infections. Future challenges 
include the research of non-toxic antimicrobial peptides that can be used as 
antimicrobial agents alone or mixed with complex (phage-hydroxyapatite). Moreover 
it will be very interesting to understand the chemical interaction between phages and 
hydroxyapatite. 
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The genes MyD88 and TIRAP encode the adaptor proteins MyD88 and
TIRAP. TIRAP plays the crucial role of activating the MyD88-dependent
pathway, which in turn controls the immune response (innate and adaptive) to
Helicobacter pylori. We looked for an association of MyD88 and TIRAP
with H. pylori infection. Cases and controls were genotyped at the polymor-
phic sites MyD88 rs6853 and TIRAP rs8177374 by real-time PCR. When
the genes were analyzed separately, only TIRAP was associated with infec-
tion. When the genes were analyzed concurrently, certain combinations of
MyD88 and TIRAP protected the host against H. pylori colonization more
efficiently than could be done by TIRAP alone.
Keywords: epistasis; Helicobacter pylori; MyD88; TIRAP
Helicobacter pylori colonizes about half the human
population worldwide [1]. As far as it is known, H. py-
lori infection is limited to the human stomach [2],
causing gastritis and more rarely peptic ulcers, gastric
carcinoma or lymphoma. It is estimated that carriers
have a 10–20% life-time risk of developing ulcers and
< 1% risk of developing gastric carcinoma [1,2].
Studies conducted on myeloid differentiation factor
88-deficient (MyD88 / ) mice have shown that the
MyD88 gene plays a major role in the immune response
(innate and adaptive) to H. pylori [3]. MyD88 is an
adaptor protein used by all Toll-like receptors (TLRs),
except TLR3 [4]. Upon recognition of conserved patho-
gen-associated molecular patterns, TLRs signal the
presence of the invading pathogen through the adaptor
molecule MyD88, which in turn activates the immune
response-inducing nuclear transcriptional factor NF-kB
[5,6]. When infected in vitro with H. pylori, dendritic
cells from MyD88 wild-type (MyD88+/+) mice express
a large number of genes regulating the immune response
(cytokine and chemokine production, antigen presenta-
tion, crosstalk between dendritic and T cells), cell differ-
entiation, and cell cycle. Under the same conditions,
dendritic cells from MyD88 / mice do not express–or
express at very low levels–the majority of these genes
(especially of immune response genes) [3]. MyD88 also
directs T-cell differentiation. Infected in vitro with
H. pylori, the dendritic cells from MyD88+/+ mice dis-
play normal levels of IL-12 and Th1 phenotype, whereas
the dendritic cells from MyD88 / mice display reduced
Th-1 phenotype and absence of IL-12, the cytokine driv-
ing T helper cells toward the Th-2 phenotype [3].
MyD88 is also required for IL-1b, IL-6, IL-10 produc-
tion [7]. An approach independent of the use of
MyD88 / mice confirms the importance of MyD88
againstH. pylori infection. In vitro, the microRNAmiR-
155 attenuates the expression of the MyD88 target pro-
tein and H. pylori-induced IL-8 [8]. As expected from
in vitro studies, MyD88 / mice infected with H. pylori
show reduced gastric inflammation and increased
Abbreviations
MAL, MyD88 adaptor-like; ORs, odds ratios; TIRAP, TIR-domain-containing adaptor protein; TLRs, Toll-like receptors.
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H. pylori colonization, compared with MyD88+/+ mice
[3]. Collectively, the above results demonstrate how
the crucial aspects of the immune response against
H. pylori are under the control of MyD88, in vitro
and in vivo.
The TIR-domain-containing adaptor protein (TIRAP)
(also called as MyD88 adaptor-like; MAL) is part of the
TLR signaling pathway. Specifically, the activation of
TLR7 and TLR9 is TIRAP-independent, while that of
TLR2 and TLR4 is MyD88-dependent [9]. It has been
suggested that the difference in TIRAP dependence might
facilitate signaling specificity among individual TLRs
[10]. The function of TIRAP is to bridge MyD88 to
TLR2 or TLR4 [4] and thus activate the MyD88-depen-
dent signaling pathway [9], which is directly involved in
the recognition of H. pylori. TLR4 binds H. pylori [11],
while TLR2 and TLR4 amplify iNOS induction [12], are
expressed at high levels in the case of gastritis [13], and
are associated with gastric cancer [14,15]. TLR2 displays
also strong anti-inflammatory activity [16]. The
rs10004195 within the TLR10/1/6 locus shows strong
association with H. pylori seroprevalence and downregu-
lates the TLR1 expression [16]. TLR1 and TLR2 form a
heterodimer, predicted to bindH. pylori lipid A [16].
Here we show that, when analyzed individually, only
TIRAP protects against infection. However, certain com-
binations of MyD88 and TIRAP – when coinherited –
strengthen protection against infection. The present data
lend support to the approach based on the concurrent
analysis of functionally related genes, which can reveal
unexpected patterns of inheritance and favor the detec-
tion of disease-associated candidate genes with negligible
effect, which escape detection when studied alone.
Materials and methods
Bacteria
Helicobacter pylori was grown as described [17]. Briefly, two
specimens (from the antrum and corpus, respectively) of the
same gastric biopsy were incubated in 1 mL Mueller-Hinton
broth supplemented with 10% horse serum (Oxoid, Milan,
Italy). Incubation (10 days) was under microaerophilic condi-
tions (CampyGen, code CN0020C; Oxoid, Basingstoke, UK).
At the end of the incubation time, cultures were streaked on
H. pylori agar (code 413193; BioM erieux SA, Marcy l’Etoile,
France) and incubated (10 days) under microaerophilic condi-
tions.
Cases and controls
Cases and controls of the preliminary and confirmatory
studies represent independent samples drawn from the same
population. Criteria for definition of cases and controls
were the same for both studies. The problem of hidden
admixture was contained (as far as possible) by including
in the study participants (cases and controls) who self-
declared themselves as of Neapolitan ancestry (participants
whose parents and grandparents were of Neapolitan ances-
try) and lived in the same neighborhood (deduced from
mail codes reported in the referral). They were referred to
the Gastroenterology Unit of the local Villa Betania hospi-
tal (Naples) for gastric biopsy between January 2012 and
December 2015. In the 8 weeks preceding gastric biopsy,
participants were not treated with antibiotics, proton pump
inhibitors or other drugs that could suppress bacterial
growth. Patients with Barrett’s esophagus or celiac disease
–conditions negatively associated with H. pylori infection
[18,19] – were excluded from the study. Cases (333 males
and 490 females; mean age: 55  10 years) were positive
by the bacteriological (see above), hematoxylin-eosin [20],
and PCR [21] tests for H. pylori infection. To exclude past
infection, H. pylori-negative participants were further tested
for the absence of the H. pylori-specific IgG antibody test
(carried out according to the manufacturer’s suggestions;
abcam; code ab108736). Controls (338 males and 623
females; mean age: 54  9) were participants negative in all
tests listed above. The study was approved by the ethic
committee of the Villa Betania hospital. Informed consent
was obtained from all participants who participated in the
study.
Genotyping
DNA was extracted from blood samples with the phenol-
chloroform method [22]. Probes and TaqMan genotyping
master mix were from Applied Biosystems (Life Technolo-
gies, Monza, Italy). Probes were specific for the polymor-
phic sites TIRAP rs8177374 and MyD88 rs6853. The PCR
program included one step at 60 °C for 30 s, one at 95 °C
for 10 min, 40 cycles at 95 °C for 15 s and at 60 °C for
1 min and one cycle at 60 °C for 30 s. To validate geno-
type accuracy, the PCR products from 10% of the sample
population plus all the participants carrying the rare geno-
types (MyD88 GG or TIRAP TT) were sequenced. Two
participants, who gave discordant results, were excluded.
RNA extraction and quantitative real-time PCR
Total RNA was extracted with the TRIzol reagent
(Ambion by Life Technologies, Thermo Fisher Scientific
Inc., Waltham, MA, USA) and reverse transcribed with the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystem, Thermo Fisher Scientific Inc.). Real-time PCR
was carried out with the Power Sybr Green PCR Master
Mix (Applied Biosystems, Thermo Fisher Scientific Inc.).
Primer pairs were designed using the PRIMER 3 software
(http://frodo.wi.mit.edu/primer3). Primer sequences are
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reported in Table S1. Expression values were normalized
against the levels of the human glyceraldehydes-3-
phosphate dehydrogenase (GAPDH). Statistical analysis
was carried out with the GRAPHPAD PRISM version 5.03
(GraphPad, La Jolla, CA, USA).
Statistical analysis
Odds ratios (ORs) and 95% confidence intervals were cal-
culated by Fisher’s exact test using the statistical package
GRAPHPAD PRISM version 5 (GraphPad). Logistic regression
was calculated using the statistical package SPSS version 19
(IBM Corporation, Armonk, NY, USA).
Odds ratios were calculated from logistic regression
model, which included H. pylori infection (as dependent
binary variable); main and interactive effects of the MyD88
rs6853 and TIRAP rs8177374 polymorphic sites; age as
potential confounders. Significance was tested by Wald’s
statistic, at a = 0.05.
Protein network analysis (interactome)
Protein network analysis (interactome) was carried out
using the STRING 10 database (http://string-db.org) [23]. The
MyD88 and TIRAP proteins network is predicted based on
neighborhood, gene fusion, co-occurrence, coexpression,
text mining, and experiments available in the literature, or
databases. The level of confidence and the maximum num-
ber of interactions between proteins were set at 0.7 and 5,
respectively.
miRNA target prediction
The homologs of regulatory RNA motifs and elements
binding the DNA sequence of the 30UTR region of the
MyD88 common or rare alleles were identified using the RE-
GRNA tool (http://regrna.mbc.nctu.edu.tw/). Of the regula-
tory RNA motifs supported by the REGRNA tool, we
analyzed the most interesting for our study (miRNA target
sites and motifs in mRNA 30UTR). The level of stringency
was that suggested by the tool.
Results
Validation of MyD88 and TIRAP as candidate
genes
The selection of MyD88 and TIRAP as candidate
genes was a multistep process. The first step consisted
in the review of H. pylori literature pertinent to our
study (see previous section). Here, we describe the
second step. The two adaptor proteins are part of the
TLR network (or transcriptome) (Fig. 1), a term
describing a complex of proteins cooperating to
accomplish a biochemical function [24]. Within the
TLR network, we identified the genes that act together
against H. pylori: MyD88 activating the downstream
signaling pathway and TIRAP bridging MyD88 to
TLR2 and TLR4 [4]. In the absence of TIRAP, the
functions of TLR2 and TLR4 – two receptors playing
a major role in the control of H. pylori infection
[3,11,13] – are in fact compromised [10]. In coopera-
tion with TRAF6, TIRAP also promotes the activation
of NF-kB and consequently of the immune response
[25]. This basic information is sufficient to illustrate
the interdependence between MyD88 and TIRAP (the
two candidate genes) and TLR2 and TLR4 (the media-
tors of the immune response against H. pylori). Inter-
actome studies provide valuable data on the protein
interactions at the cell level. Yet they are prone to
errors [26–28]. We therefore tried to support our can-
didate gene selection strategy using an independent
approach, the crystal structure of the MyD88-IRAK4-
IRAK2 complex analysis [29]. In this context, My
D88, TIRAP, and the other Toll/IL-1 receptor (TIR)
domain-containing adaptors cooperate to create a plat-
form favoring phosphorylation and NF-kB activation by
the IL-1 receptor-associated kinases IRAK2 and
IRAK4. Gene ontology analysis confirms the results
described above (Table 1) and adds new ones (Table S2),
such as the tendency of MyD88 and TIRAP proteins
toward hetero-dimerization. This last finding, confirmed
by different authors using different techniques [4,6,30],
certainly adds weight to the hypothesis of a functional
phenotypic interaction between the MyD88 and TIRAP
molecules. On the basis of the above considerations, we
selectedMyD88 andTIRAP as our candidate genes.
IL1R1
TRAF6
TIRAP
TLR4
IRAK4
IRAK2
MYD88
Fig. 1. Protein network analysis of human MyD88 and TIRAP
proteins. Lines indicate interactions between proteins (or nodes).
Nodes provide access to the three dimensional structure of
proteins and additional information.
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Characterization of the SNPs selected for study
Of the 12 SNPs tested (MyD88: rs4988457; rs14814
9492; rs56269210; rs56271803; rs4988458; TIRAP: rs81
77400; rs8177350; rs8177351; rs8177369; rs8177373),
only two (MyD88 rs6853 and TIRAP rs8177374) dis-
played a frequency of the rare allele > 0.05, a requisite
for inclusion of SNPs in an association study [31]. The
two SNPs are located on chromosomes 3 (location:
38184370; 30UTR; NCBI) and 11 (location: 126162843;
transition substitution; NCBI9), respectively. The
MyD88 rs6853 polymorphism is reported to influence
tuberculosis [32], the electroencephalogram pattern
during anesthesia [33], and cognitive dysfunctions dur-
ing chemotherapy [34] The TIRAP rs81773749 poly-
morphism is reported to confer resistance to malaria,
tuberculosis, bacteremia, and invasive pneumococcal
disease [35]. However, protection against tuberculosis
has been confirmed by some, but not all, subsequent
studies [32,36,37]. Recently, another TIRAP
polymorphic site (rs793276) was associated with pre-
disposition to gastric cancer [38].
Single locus analysis
The exploratory test hinted at the absence of the rare
homozygous genotypes (MyD88 GG and TIRAP TT)
among cases and at a potential protective role of the
TIRAP CT genotype against H. pylori infection (OR:
0.53; P: 9.1 9 10!5; Table 2).
Association studies suffer from scarce reproducibil-
ity [39,40]. We therefore carried out a replication
study, which supported the results from the prelimi-
nary study. It confirmed the protective role of the
TIRAP CT genotype against H. pylori infection (OR:
0.56; P: 6 9 10!4; Table 3) and the absence of the rare
MyD88 GG and TIRAP TT genotypes among cases
(Tables 2 and 3). A recent study also describes the
protective role played against H. pylori by the rare
allele of the rs10004195 at the TLR1/10/6 locus [16].
Table 1. Gene Ontology of terms common to MyD88 and TIRAP proteins.
Gene name Gene name Gene ontology terms Categorya Description
MyD88 TIRAP GO:0070935 P 30-UTR-mediated mRNA stabilization
MyD88 TIRAP GO:0032760 P Positive regulation of tumor necrosis factor production
MyD88 TIRAP GO:0038123 P Toll-like receptor TLR1:TLR2 signaling pathway
MyD88 TIRAP GO:0044130 P Negative regulation of growth of symbiont in host
MyD88 TIRAP GO:0005829 C Cytosol
MyD88 TIRAP GO:0043123 P Positive regulation of I-kappaB kinase/NF-kappaB cascade
MyD88 TIRAP GO:0046330 P Positive regulation of JNK cascade
MyD88 TIRAP GO:0051092 P Positive regulation of NF-kappaB transcription factor activity
MyD88 TIRAP GO:0002755 P MyD88-dependent toll-like receptor signaling pathway
MyD88 TIRAP GO:0050830 P Defense response to Gram-positive bacterium
MyD88 TIRAP GO:0038124 P Toll-like receptor TLR6:TLR2 signaling pathway
a Gene Ontology associated categories: P (process); C (component).
Table 2. Association of MyD88 rs6853 and TIRAP rs8177374 polymorphic sites with Helicobacter pylori infection. Preliminary study.
Genes Status Number of individuals in each genotype Total HWE (P)
Allelic frequency
OR (CI)C P-valueCoa Rab
AA AG GG
MyD88 Cases 280 142 0 422 17.27
(3.2 9 10 5)
0.83 0.17 AG vs AA
1.19 (0.9–1.5)
0.22
Controls 345 147 16 508 0.01
(0.92)
0.82 0.18
CC CT TT
TIRAP Cases 347 75 0 422 4.01
(0.045)
0.91 0.09 CT vs CC
0.53 (0.38–0.73)
9.1 9 10 5
Controls 348 141 5 494 5.16
(0.023)
0.85 0.15
a Common alleles (MyD88: A; TIRAP: C).
b Rare alleles (MyD88: G; TIRAP: T).
c Confidence intervals.
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Finally, the replication study confirmed lack of associ-
ation between MyD88 and the H. pylori infection
(OR: 1.16; P: 0.29; Table 3).
MyD88-TIRAP epistasis
The adaptor protein TIRAP is required for the
MyD88-dependent activation of TLR2 and TLR-4
[4,9], which in turn exert a crucial role in the immune
response to H. pylori [3]. A tight cooperation between
the TIRAP and MyD88 molecules is also inferred
from their ability to form heterodimers [4,6,30]. We
therefore looked for an epistatic interaction between
the MyD88 and TIRAP. MyD88, when alone, did not
influence infection (Tables 4 and 5). Instead, in certain
combinations with TIRAP, MyD88 markedly influ-
enced the risk of infection (Tables 4 and 5). In the pre-
liminary and the replication studies, the intergenic
interactions (MyD88/TIRAP AG/CT vs MyD88/
TIRAP AA/CC) yielded the following ORs for infec-
tion: preliminary study: 0.16 (P: 5.3 9 10 6); replica-
tion study: 0.12 (6.3 9 10 8). In conclusion, MyD88
displays its effect on H. pylori only when analyzed
concurrently with TIRAP.
After correction from age-confounding effect, dou-
ble heterozygosity (MyD88/TIRAP AG/CT vs all the
remaining allele combinations) still protected against
infection (preliminary study: OR: 0.19; P: 2.4 9 10 4;
replication study: OR: 0.14; P: 2 9 10 6). The single
heterozygote MyD88/TIRAP AG/CC (vs all the
remaining allele combinations) instead predisposed to
infection (preliminary study: OR: 1.87; P: 6 9 10 5;
replication study: OR: 2.36; P: 8.3 9 10 8), a result
which clearly shows the protective role of the TIRAP
CT genotype (Tables S3 and S4).
When the preliminary and replication studies were
merged, the MyD88 P value stands nonsignificant
(0.22; 0.29; 0.08; Tables 2, 3, and 6); the TIRAP P
value instead becomes significantly smaller
(9.1 9 10 5; 6 9 10 4; 2 9 10 7; Tables 2, 3, and 6);
so do also the P values of the MyD88-TIRAP AG/CT
and AG/CC epistatic interactions: (5.3 9 10 6;
6.3 9 10 8; 5.9 9 10 13; Tables 4, 5, and 7) and (0.05;
8 9 10 4; 10 4; Tables 4, 5, and 7), respectively. In
Table 3. Association of MyD88 rs6853 and TIRAP rs8177374 polymorphic sites with Helicobacter pylori infection. Replication study.
Genes Status Number of individuals in each genotype Total HWE (P)
Allelic frequency
OR (CI)c P-valueCoa Rab
AA AG GG
MyD88 Cases 216 185 0 401 36.05
(0)
0.77 0.23 AG vs AA
1.16 (0.88–1.53)
0.29
Controls 248 182 23 453 2.01
(0.15)
0.75 0.25
CC CT TT
TIRAP Cases 328 73 0 401 4.02
(0.044)
0.91 0.09 CT vs CC
0.56 (0.40–0.78)
6 9 10 4
Controls 320 126 7 453 1.88
(0.17)
0.85 0.15
a Common alleles (MyD88: A; TIRAP: C).
b Rare alleles (MyD88: G; TIRAP: T).
c Confidence intervals.
Table 4. Interaction between MyD88 rs6853 and TIRAP rs8177374
polymorphic sites and Helicobacter pylori infection. Preliminary
study.
Status Interactions ORb P-value
Allelic interactions
Infection MyD88 (AG vs AA) 1.19 0.22
TIRAP (CT vs CC) 0.53 9.1 9 10 5
Epistatic interactions
MyD88(AG) by TIRAP(CT)a 0.16 5.3 9 10 6
MyD88(AG) by TIRAP(CC)a 1.37 0.05
MyD88(AA) by TIRAP(CT)a 0.75 0.12
a Reference genotype: MyD88(AA)/TIRAP(CC).
b Odds ratio.
Table 5. Interaction between MyD88 rs6853 and TIRAP rs8177374
polymorphic sites and Helicobacter pylori infection. Replication
study.
Status Interactions ORb P-value
Allelic interactions
Infection MyD88 (AG vs AA) 1.16 0.29
TIRAP (CT vs CC) 0.56 6 9 10 4
Epistatic interactions
MyD88(AG) by TIRAP(CT)a 0.12 6.3 9 10 8
MyD88(AG) by TIRAP(CC)a 1.72 8 9 10 4
MyD88(AA) by TIRAP(CT)a 1.27 0.25
a Reference genotype: MyD88(AA)/TIRAP(CC).
b Odds ratio.
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conclusion, as expected, combining the two sets of
data, makes the study more robust.
Different mRNA expression levels of the rs6853
alleles
The polymorphic sites located in the nonprotein cod-
ing region–such as the MyD88 rs6853–often influence
the phenotype by binding regulatory signals [41]. We
therefore tested the mRNA expression levels of the
three MyD88 genotypes. We found that the GG geno-
type is significantly downregulated compared with the
AA and AG genotypes (GG vs AA; P < 10 4; GG vs
AG; P: 3.6 9 10 3) (Fig. 2). Using comparative geno-
mics, we then attempted to identify the regulatory fac-
tors binding the rs6853 30UTR. Of the nine factors
examined (Table 8), two – the miR-526b-5p [42] and
Table 6. Association of MyD88 rs6853 and TIRAP rs8177374 polymorphic sites with Helicobacter pylori infection. Combined study.
Genes Status Number of individuals in each genotype Total HWE (P)
Allelic frequency
OR (CI)c P-valueCoa Rab
AA AG GG
MyD88 Cases 496 327 0 823 50.58
(0)
0.80 0.20 AG vs AA
1.18 (0.97–1.44)
0.083
Controls 593 329 39 961 0.63
(0.42)
0.79 0.21
CC CT TT
TIRAP Cases 675 148 0 823 8.03
(4.6 9 10 3)
0.91 0.09 CT vs CC
0.54 (0.43–0.68)
2 9 10 7
Controls 668 267 12 947 6.7
(9.6 9 10 3)
0.85 0.15
a Common alleles (MyD88: A; TIRAP: C).
b Rare alleles (MyD88: G; TIRAP: T).
c Confidence intervals.
Table 7. Interaction between MyD88 rs6853 and TIRAP rs8177374
polymorphic sites and Helicobacter pylori infection. Combined
study.
Status Interactions ORb P-value
Allelic interactions
Infection MyD88 (AG vs AA) 1.18 0.08
TIRAP (CT vs CC) 0.54 2 9 10 7
Epistatic interactions
MyD88(AG) by TIRAP(CT)a 0.14 5.9 9 10 13
MyD88(AG) by TIRAP(CC)a 1.53 10 4
MyD88(AA) by TIRAP(CT)a 0.94 0.73
a Reference genotype: MyD88(AA)/TIRAP(CC).
b Odds ratio.
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Fig. 2. Different mRNA expression levels of the MyD88 rs6853
genotypes. Results are representative of three independent
experiments. Each value represents the mean " SD of
determinations carried out in triplicate on 10 participants.
Table 8. Prediction of functional regulatory targets on the MyD88 common allele.
Motif Type Motif Name Position Length Sequence
Transcriptional regulatory motif TTF-1_(Nkx2-1) 1590–1601 12 atctcaagaggc
microRNA target sites hsa-miR-18a-5p 1588–1607 20 ccatctcaagaggcatcttc
microRNA target sites hsa-miR-18b-5p 1585–1607 23 aagccatctcaagaggcatcttc
microRNA target sites hsa-miR-526b-5p 1580–1599 20 ttttaaagccatctcaagag
microRNA target sites hsa-miR-1183 1585–1615 31 aagccatctcaagaggcatcttctacatgtt
microRNA target sites hsa-miR-2682-3p 1583–1602 20 taaagccatctcaagaggca
microRNA target sites hsa-miR-3668 1592–1613 22 ctcaagaggcatcttctacatg
microRNA target sites hsa-miR-4657 1588–1613 26 ccatctcaagaggcatcttctacatg
microRNA target sites hsa-miR-1273f 1573–1595 23 ctgggcattttaaagccatctca
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the transcriptional regulatory factor 1 (TTF-1) [43] –
are predicted to bind the 30UTR of the common, but
not the rare rs6853 allele (Tables 8 and 9). Since the
rs6853 common allele is not downregulated, miR-
526b-5p (which downregulates the target mRNA
expression) cannot explain our results (Fig. 2). With
its property of modulating the expression of a large
number of targets [43], TTF-1 remains the factor that
potentially could explain the mechanism of the rare
allele downregulation.
Inflammatory molecules expression levels among
cases
The mRNA levels of the IL-6, COX-2, TNF-a, and
IL-1b (collectively referred to as inflammatory mole-
cules) varied among the MyD88-TIRAP genotypes.
The inflammatory molecules were measured by real-
time PCR and compared with the most frequent geno-
type among cases (AA/CC). The double heterozygous
cases (AG/CT) displayed significantly (P < 10!4) lower
levels of the four inflammatory molecules (in particular
of IL-6) compared with the double homozygous cases
(AA/CC) (Fig. 3A). This result indicates: first, that the
relative resistance of the AG/CT cases (OR: 0.12; P:
6.3 9 10!8; Table 5) is associated with a marked low
level of IL-6; second, that the MyD88-TIRAP interac-
tion is evident at the statistical (Tables 4 and 5) as well
as the phenotypic levels (Fig. 3A). Furthermore, single
heterozygous cases (AA/CT and AG/CC) display sig-
nificantly higher levels of IL-6 and COX-2 and – at
the same time – significantly (P < 10!4) lower levels of
TNF-a and IL-1b compared with the double homozy-
gous cases (Fig. 3B). These results are in line with the
known role played by IL-6 in downregulating TNF-a
and IL-1b [44,45] and upregulating COX-2 [46].
Discussion
When the genesMyD88 and TIRAP were analyzed indi-
vidually, the MyD88 results failed to correlate with
H. pylori. Instead, TIRAP – in the heterozygous form
CT – confers resistance to infection (Tables 2 and 3). The
MyD88 and TIRAP proteins are part of the TLR signal-
ing pathway (Fig. 1). Their common function is to acti-
vate TLR2 and TLR4, two major receptors regulating
innate and adaptive immune responses of the host
against H. pylori [3,8,11,12]. In addition, the MyD88
and TIRAP proteins form heterodimers [4,6,30]. This
evidence invited us to look for a potential epistatic
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Fig. 3. Levels of IL-6, COX-2, TNF-a, and IL-1b mRNA in MyD88-
TIRAP double (A) or single heterozygous (B) genotypes. Reference
genotype: AA/CC. Results are representative of three independent
experiments. Each value represents the mean " SD of
determinations carried out in triplicate on 10 participants AA/CC,
AA/CT, AG/CC or on six participants AG/CT. ***P-value < 10!3.
Table 9. Prediction of functional regulatory targets on the MyD88 rare allele.
Motif Type Motif Name Position Length Sequence
microRNA target sites hsa-miR-18a-5p 1588–1607 20 ccatctcgagaggcatcttc
microRNA target sites hsa-miR-18b-5p 1585–1607 23 aagccatctcgagaggcatcttc
microRNA target sites hsa-miR-1183 1585–1615 31 aagccatctcgagaggcatcttctacatgtt
microRNA target sites hsa-miR-2682-3p 1583–1602 20 taaagccatctcgagaggca
microRNA target sites hsa-miR-3668 1592–1613 22 ctcgagaggcatcttctacatg
microRNA target sites hsa-miR-4657 1588–1613 26 ccatctcgagaggcatcttctacatg
microRNA target sites hsa-miR-1273f 1573–1595 23 ctgggcattttaaagccatctcg
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interaction between the corresponding MyD88 and
TIRAP genes, a contention supported by a previous
study where the same genes acted epistatically against
human pulmonary tuberculosis [32]. Indeed, both in the
preliminary and the replication studies described here,
certain combinations of MyD88 and TIRAP protected
the host against H. pylori colonization more efficiently
than TIRAP alone could do, thus providing evidence of a
nonadditive epistatic interaction occurring between the
two genes (Tables 4 and 5). The epistatic interaction
observed at the statistical level was also confirmed at the
phenotypic level (Figs 3A and 3B).
The hypothesis that the epistasis described here
could reflect a statistical artifact is unlikely. First, the
property of the MyD88 and TIRAP adaptor proteins
to form heterodimers has been demonstrated in inde-
pendent studies and using different approaches, such
as crystal structure analysis [4], coimmunoprecipitation
and confocal microscopy [6]. Second, physical associa-
tion between proteins coded by independent genes con-
stitutes robust and unbiased evidence of epistasis [24].
Third, the same polymorphic sites acted epistatically
also against M. tuberculosis [32]. In the near future, we
will measure the epistatic effects potentially occurring
between additional MyD88 and TIRAP polymorphic
sites, which we recently have identified. The study
might lead to the discovery of new interactions influ-
encing phenotypes correlated with H. pylori infection.
In vitro studies on biopsy specimens might also lead to
the discovery of possible perturbations of epistasis
occurring in the presence of H. pylori and the potential
effect of host genetic polymorphisms on this pathogen.
The finding that MyD88 analyzed in isolation from
TIRAP does not influence H. pylori introduces further
interesting insights about this phenomenon. First, that
epistasis can help to discover a new category of resis-
tance genes, those with individual effects too weak to
be detected when the gene is studied in isolation (this
article). Second, that lack of replication of genetic
association studies might in part reflect the presence of
epistasis, a phenomenon that occurs more frequently
than suspected [47]. Indeed, if the frequencies of two
genes functionally linked by epistasis vary across pop-
ulations, the frequencies of specific combinations also
vary, contributing to the replication failure of associa-
tion studies [48].
MyD88 and TIRAP confer resistance to H. pylori
(this study) and M. tuberculosis [32]. Numerous dis-
eases (infectious or autoimmune) are known to be
influenced by the same genetic marker [35,49,50]. We
add that one more potential benefit that might derive
from studying genes coding for adaptor molecules is to
find one therapy for several diseases. These molecules
are in fact part of a hub integrating signals from a
multitude of pathogens.
We feel cautiously optimistic about the reproducibil-
ity of the present study. Our optimism relies on the
following facts. The preliminary and replication stud-
ies provide concurrent results; replication of results in
an independent sample is the standard measure of
replication [51]. The genes selected for study have
strong biological plausibility and belong to the same
biochemical pathway. Cases and controls have been
accurately classified (cases being positive by the micro-
biological, PCR, and hematoxylin-eosin tests and con-
trols negative by the same tests). The ever present
hidden heterogeneity problem was contained (as far as
possible) by including in the study participants (cases
and controls), who self-declared themselves as of
Neapolitan ancestry and lived in the same neighbor-
hood.
In conclusion, the study shows first, that the two
rare genotype (MyD88 GG and TIRAP TT) are not
represented among cases (suggesting that they might
confer total resistance to H. pylori infection). Second,
double heterozygotes (MyD88-TIRAP AG/CT) dis-
play relative resistance to the pathogen (replication
study; OR: 0.12; P: 6.3 9 10 8; Table 5) and are
characterized by lower levels of IL-6, COX-2, TNF-a,
and IL-1b compared with double homozygotes
(Fig. 3A). Third, double heterozygotes cases are char-
acterized by a very low expression level of IL-6, a
condition that by itself potentially could function as
marker of relative resistance to H. pylori. However,
we caution the reader that the clinical relevance of
these findings needs to be first validated by indepen-
dent studies on populations of different ethnicities.
We finally caution that future replication of this study
demands that H. pylori is detected using the bacterio-
logical test (as we did). Helicobacter pylori diagnosis
based on seroconversion could lead to noncomparable
results.
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ABSTRACT
Mushrooms produce a wide range of bioactive polysaccharides, 
dierent from each other in chemical structure and biological eects. In 
the last years, the idea to develop functional foods or drugs containing 
fungal polysaccharides is attracting great attention. Fruiting bodies of 
Basidiomycetes Ganoderma lucidum are commonly used in Oriental 
medicine to treat several disorders. G. lucidum polysaccharides – 
mainly β-glucans and heteroglycans – have numerous biological 
properties such as antitumour and immunomodulatory activities. 
This report shows, by gene expression analyses and bioenergetic 
assays, immunomodulatory properties and capacity to improve 
glucose metabolism of a water-soluble heteroglycan extracted from 
mycelium of an Italian isolate of G. lucidum. The "ndings suggest the 
use of the heteroglycan as probiotic or ingredient in functional foods, 
being easy to produce and disperse in a food matrix thanks to its 
water-solubility. Heteroglycan could exert protective eects in pro-
in#ammatory conditions and bene"ts for people characterised by 
suppressed immune response.
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1. Introduction
Fungi play an important role in several aspects of human life, in particular as source of ther-
apeutics and food. Many fungi naturally produce antibiotics, which are able to inhibit the 
growth of the competing micro-organisms. The edible fungi (mushrooms) are often favoured 
in the human diet because they are poor in fat and rich in proteins, minerals and !bres (Manzi 
et al. 1999). Fungal cell walls are rich in bioactive polysaccharides (glycans), which are di"er-
ent from each other in chemical structure and biological activity (Herrera 2012). Glucans are 
the most abundant (and most studied as well) fungal glycans and they have only D-glucose 
as structural component: it is possible to distinguish linear or branched ˞ -, β- as well as mixed 
˞,β-glucans (Synytsya & Novak 2014). β-glucans of several fungi show numerous biological 
properties, including antitumour, antimicrobial, antidiabetic, antihypercholesterolemic and 
immunomodulating activities (Wasser 2011; Chang & Wasser 2012). Krestin – a heteroglycan 
isolated from Polysticus versicolor and consisted of glucose and other simple sugars – has 
antitumour, antihepatitis and antihyperlipidemic properties. Pachymaran – a heteroglycan 
puri!ed from Poria cocos and consisted of glucose, galactose and mannose units – has anti-
tumour activity and is used to treat insomnia and schizophrenia. Grifola frondosa heterogly-
cans – consisted of glucose, xylose, fucose, galactose and mannose units – show anticancer 
and immunomodulatory properties (Zhou et al. 2014).
Biological properties of fungal glycans vary depending on their water solubility, chemical 
composition and conformational structure (Polishchuk & Kovalenko 2009), but the basic 
requirements for biological activity are not still completely clear (Brown & Gordon 2003). 
Eight fungal glycans-based drugs are marketed in China, each of them displays unique pol-
ysaccharide composition and biological e"ects (Zhou et al. 2014). In general, water-soluble 
glycans are considered pharmacologically more active (Hu et al. 2013). Moreover, isolation 
methods may in$uence the features of the glycans and di"erences can be observed among 
compounds di"erentially isolated from the same source (Volman et al. 2008).
Ganoderma lucidum (Curtis) P. Karst is a lignocellulose-degrading mushroom of the 
Polyporaceae family. Over the past centuries, its fruiting bodies have been widely used in 
the Chinese and Japanese traditional medicine for the treatment of several disorders (such 
as gastritis, diabetes, hypercholesterolemia, hepatitis and cardiovascular problems). Modern 
research – by con!rming the antitumour, antihypertensive, antidiabetic and immunomod-
ulatory properties of G. lucidum extracts (Boh et al. 2007; Rex 2014) – has sensibly contributed 
to the success of this mushroom as nutraceutical so that the annual sale of G. lucidum-derived 
products is estimated about 2.5 billion U.S. dollars (Li et al. 2013). The major bioactive com-
pounds of Ganoderma species are polysaccharides (such as β-glucans, glycoproteins and 
heteroglycans) and triterpenoids (Nie et al. 2013; Ruan et al. 2014), both usually isolated 
from the fruiting bodies of Asian isolates. In particular, polysaccharides are known for their 
anticancer and antimicrobial e"ects and their capacity to enhance the host immune system 
(Lin 2005), but there are few available studies about polysaccharides obtained from mycelium 
of European isolates of G. lucidum (Boh et al. 2007).
This study investigated immunomodulatory properties and capacity to improve glucose 
metabolism of a water-soluble heteroglycan (HGlyc), extracted from the mycelium of an 
Italian isolate of G. lucidum. For this purpose, gene expression analyses and two di"erent 
bioenergetic assays were carried out in a cell line model. The report also describes an alkaline 
method, that combines purity with high yield, for the extraction of HGlyc and the chemical 
characterisation by NMR spectroscopy.
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2. Results and discussion
2.1. Extraction of HGlyc
Eight grams of dry material were obtained from 80 g of fresh mycelium. About 20 mg of a 
water-soluble heteroglycan (composed by units of several monosaccharides) were extracted 
from 2 g of lyophilised mycelium. Simplicity and high yield suggest the possibility to use 
the method for a large-scale production of HGlyc from the mycelium of G. lucidum.
2.2. Monosaccharide composition and 1H NMR spectrum
Preliminary studies were performed to determine the structure of HGlyc. The monosaccharide 
composition was determined by complete hydrolysis of the glycan at 100°C in water/TFA, 
followed by NaBH
4
 reduction and acetylation with acetic anhydride. GC–MS analysis of the 
resulting alditol acetates showed the glycan to be composed of glucose, mannose, fucose, 
xylose and galactose, in the molar ratios 58:16:14:7:5 (see Experimental Part for details).
The 1H NMR spectrum of the glycan in D
2
O was recorded to obtain information about the 
anomeric con"gurations of the sugars. Firstly, the anomeric protons were identi"ed from 
their correlation with the relevant anomeric carbons using an HSQC 2D NMR (Figure S1). To 
make 1H signals as sharp as possible, the spectrum was acquired at 70°C. Even so, all signals 
appeared as unresolved broad singlets, and proton-proton coupling constants (the most 
reliable parameter for determination of anomeric con"gurations) could not be measured. 
Therefore, the determination of anomeric con"guration was based on chemical shifts of 
anomeric protons (typically ͣ 5.2–4.9 for ˞-sugars and ͣ 4.6–4.3 for β-sugars) (Synytsya & 
Novak 2014). The anomeric region of the spectrum of HGlyc was quite complex (Figure S1), 
with multiple signals of di$erent intensity both in the region of ˞-sugars and β-sugars. 
Integration showed an approximate 3:1 ratio between the overall areas of the signals of 
˞-anomeric protons and β-anomeric protons, showing that most sugars were in the ˞ 
con"guration.
A more detailed analysis of the structure of HGlyc is in progress and the results will be 
reported in the due course.
2.3. Cell viability and NO
2
 measurements
At the concentrations of 200, 500 and 1000 μg mL−1, HGlyc did not a$ect cell viability, while 
the positive control (THP-1 cells treated with 50% ethanol) showed a 70% reduction of cell 
viability. Compared to the cells treated only with 10 μg mL−1 LPS, HGlyc (at the concentration 
of 200 μg mL−1) reduced NO
2
 production by 67% (Figure S2).
2.4. Bioenergetic analyses
Basal and maximal glycolysis values and glycolytic capacity were calculated (Figure 1(a–b)). 
Upon glucose addition, the medium of LPS-treated cells showed a signi"cant increase of 
acidi"cation (422%), compared to untreated cells, indicating a higher rate of basal glycolysis. 
Instead, when cells were treated with HGlyc and then LPS, a reduction of basal glycolysis 
was observed (53%). Next, incubating cells with oligomycine, the property of HGlyc to curb 
the maximal glycolysis was measured. Again, the HGlyc signi"cantly reduced the maximal 
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glycolysis (44%). Finally, to measure the glycolytic capacity of the cells, 2-DG reagent was 
added. As expected, the glycolytic capacity was also signi!cantly reduced (36%).
Glucose-oxidase activity, an index of glucose uptake in cells, was evaluated in eight exper-
imental conditions (Figure 1(c)). Glucose level was markedly higher in cells treated with LPS 
or prednisone (1 h and 12 h), compared to untreated cells (58.5, 100 and 83%, respectively). 
LPS and prednisone are reported to determine an increase of glucose uptake, up-regulating 
the expression of glucose-transporter genes (Chung 2008; Hwang & Weiss 2014). Further, 
the property of HGlyc to curb the glucose uptake was measured: in cells treated with HGlyc 
and then with LPS or prednisone (1 h and 12 h), a reduction of glucose level (52, 66 and 95%, 
respectively) was registered. Cells treated only with HGlyc showed a glucose level lower 
(66%) than untreated cells.
Taken together, NO
2
 measurements and ECAR values showed the capacity of HGlyc to 
reduce stress in in"ammatory conditions induced by LPS in the model cell line. In our knowl-
edge, ECAR analysis was used for the !rst time to investigate the e#ect of a fungal polysac-
charide on cellular glucose metabolism. In addition, GOA assay indicated a hypoglycemic 
activity of HGlyc. Ability to reduce glucose levels in blood was already reported for polysac-
charides from G. lucidum (He et al. 2006; Jia et al. 2009).
2.5. Gene expression
The expression levels of four important pro-in"ammatory cytokines (TNF-˞, IL-6, IL1-˞ and 
IL-1β) were measured. HGlyc was used at the optimal concentration of 200 μg mL−1. The cells 
incubated with HGlyc and LPS displayed down-regulation of three cytokine genes: TNF-˞ 
by 28.5%; IL-6 and IL-1˞ by 94%, compared to the positive control (cells incubated only with 
LPS). On the contrary, IL-1β gene was up-regulated by 40%. The cytokines mRNA level was 
identical in cells treated with HGlyc and in untreated cells. The analysis was extended to the 
mediator of in"ammation COX-2, that resulted signi!cantly down-regulated (33% compared 
to positive control) (Figure 2). Down-regulation of pro-in"ammatory molecules mediated 
Figure 2. Expression levels of TNF-˞, IL-6, IL1-˞, IL-1β and COX-2 genes involved in immune response. The 
gene expression was evaluated in: untreated THP-1 cells; cells treated 12 h with HGlyc 200 μg mL−1; cells 
treated 1 h with LPS (10 μg mL−1); cells treated with HGlyc and then LPS. Values represent the average 
determination ± SE for three experiments, carried out in triplicate. A pool of THP-1 untreated cells was 
used as a calibrator for real time PCR experiments. *** = p < 0.0001. P-values express statistical signiﬁcance 
for LPS-treated cells versus untreated cells, and for cells treated with HGlyc + LPS versus LPS-treated cells.
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by G. lucidum polysaccharides was described in a previous report (Wang et al. 2014), in which 
water insoluble β-glucans extracted from fruit bodies reduced LPS-induced in"ammation 
in mouse macrophages.
3. Conclusions
Di#erent types of bioactive glycans – which vary in monosaccharide composition, glycosidic 
bonds, tertiary structure and molecular weight – have been puri$ed from fruiting bodies 
of G. lucidum (Zhou et al. 2014). This study reports a method – easily reproducible – for the 
extraction of a water-soluble heteroglycan (HGlyc) from the mycelium of G. lucidum. HGlyc 
has glucose as major monosaccharide and it contains mannose, fucose, xylose and galac-
tose. HGlyc exhibited the capacity to signi$cantly reduce the in"ammation induced by LPS 
in THP-1 cells in a dose-dependent manner. In cells incubated with HGlyc and then LPS, the 
expression levels of the mediators of in"ammation TNF-˞, IL-6, IL1-˞ and COX-2 were sig-
ni$cantly down-regulated, compared to LPS-treated cells. On the contrary, HGlyc up- 
regulated the expression of IL-1β. This result is consistent with the property of fungal 
glucans to activate the transcription of this cytokine via the dectin-1-dependent pathway 
(Kankkunen et al. 2010). Bioenergetics assays and NO
2
 measurements also con$rmed the 
property of HGlyc to reduce cellular stress in in"ammatory conditions, indicating at same 
time a hypoglycemic activity. HGlyc from G. lucidum are able to control excessive in"am-
mation and to establish a homeostasis between pro- and anti-in"ammatory responses, so 
they could be used as a probiotic or as ingredient in functional foods, with protective e#ects 
in pro-in"ammatory conditions and bene$ts for people characterised by suppressed 
immune response.
In the last years, the idea to develop functional foods or drugs containing fungal pol-
ysaccharides is attracting great attention (Aida et al. 2009). Numerous health products 
based on G. lucidum are internationally marketed (Chang & Buswell 2008). Fruiting bodies 
are very rare in nature, so the amount of wild G. lucidum is not su%cient to meet the 
demands in international markets and its cultivation in vitro is essential. In the present 
work, a water-soluble heteroglycan was e%ciently and economically isolated from the 
mycelium of G. lucidum, suggesting the possibility of a large scale production by sub-
merged cultivations in bio-reactors. The bene$ts of liquid cultivations include: i) the ability 
to manipulate the medium to optimise mycelium growth; ii) reduced costs; iii) shorter 
cultivation time and lower risk of contamination, compared to the cultivation of fruiting 
bodies.
Furthermore, water solubility makes HGlyc easier to disperse in a food matrix and so more 
favourable for therapeutic applications, because they are easy to be absorbed by the organ-
ism and consequently more e#ective.
However, further studies are needed and these concepts should be con$rmed in future 
trials in vivo using realistic food matrices.
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